Differentiation antigens found on thymocytes and on cytotoxic and suppressor T-lymphocytes. CD8 antigens are members of the immunoglobulin supergene family and are associative recognition elements in MHC (Major Histocompatibility Complex) Class I-restricted interactions.
Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA).
A membrane glycoprotein and differentiation antigen expressed on the surface of T-cells that binds to CD40 ANTIGENS on B-LYMPHOCYTES and induces their proliferation. Mutation of the gene for CD40 ligand is a cause of HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 1.
A member of the tumor necrosis factor receptor superfamily with specificity for CD40 LIGAND. It is found on mature B-LYMPHOCYTES and some EPITHELIAL CELLS, lymphoid DENDRITIC CELLS. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centers. Mutations of the gene for CD40 antigen result in HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 3. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
Acidic sulfated integral membrane glycoproteins expressed in several alternatively spliced and variable glycosylated forms on a wide variety of cell types including mature T-cells, B-cells, medullary thymocytes, granulocytes, macrophages, erythrocytes, and fibroblasts. CD44 antigens are the principle cell surface receptors for hyaluronate and this interaction mediates binding of lymphocytes to high endothelial venules. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
Costimulatory T-LYMPHOCYTE receptors that have specificity for CD80 ANTIGEN and CD86 ANTIGEN. Activation of this receptor results in increased T-cell proliferation, cytokine production and promotion of T-cell survival.
Ratio of T-LYMPHOCYTES that express the CD4 ANTIGEN to those that express the CD8 ANTIGEN. This value is commonly assessed in the diagnosis and staging of diseases affecting the IMMUNE SYSTEM including HIV INFECTIONS.
Glycolipid-anchored membrane glycoproteins expressed on cells of the myelomonocyte lineage including monocytes, macrophages, and some granulocytes. They function as receptors for the complex of lipopolysaccharide (LPS) and LPS-binding protein.
A bifunctional enzyme that catalyzes the synthesis and HYDROLYSIS of CYCLIC ADP-RIBOSE (cADPR) from NAD+ to ADP-RIBOSE. It is a cell surface molecule which is predominantly expressed on LYMPHOID CELLS and MYELOID CELLS.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
Glycoproteins expressed on cortical thymocytes and on some dendritic cells and B-cells. Their structure is similar to that of MHC Class I and their function has been postulated as similar also. CD1 antigens are highly specific markers for human LANGERHANS CELLS.
A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CTLA-4 ANTIGEN with high specificity and to CD28 ANTIGEN with low specificity. The interaction of CD80 with CD28 ANTIGEN provides a costimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.
Glycoprotein members of the immunoglobulin superfamily which participate in T-cell adhesion and activation. They are expressed on most peripheral T-lymphocytes, natural killer cells, and thymocytes, and function as co-receptors or accessory molecules in the T-cell receptor complex.
Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CD28 ANTIGEN with high specificity and to CTLA-4 ANTIGEN with low specificity. The interaction of CD86 with CD28 ANTIGEN provides a stimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.
A tumor necrosis factor receptor subtype found in a variety of tissues and on activated LYMPHOCYTES. It has specificity for FAS LIGAND and plays a role in regulation of peripheral immune responses and APOPTOSIS. Multiple isoforms of the protein exist due to multiple ALTERNATIVE SPLICING. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.
Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Cell-surface glycoprotein beta-chains that are non-covalently linked to specific alpha-chains of the CD11 family of leukocyte-adhesion molecules (RECEPTORS, LEUKOCYTE-ADHESION). A defect in the gene encoding CD18 causes LEUKOCYTE-ADHESION DEFICIENCY SYNDROME.
The 140 kDa isoform of NCAM (neural cell adhesion molecule) containing a transmembrane domain and short cytoplasmic tail. It is expressed by all lymphocytes mediating non-MHC restricted cytotoxicity and is present on some neural tissues and tumors.
A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. They are found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
A cell adhesion protein that was originally identified as a heat stable antigen in mice. It is involved in METASTASIS and is highly expressed in many NEOPLASMS.
Leukocyte differentiation antigens and major platelet membrane glycoproteins present on MONOCYTES; ENDOTHELIAL CELLS; PLATELETS; and mammary EPITHELIAL CELLS. They play major roles in CELL ADHESION; SIGNAL TRANSDUCTION; and regulation of angiogenesis. CD36 is a receptor for THROMBOSPONDINS and can act as a scavenger receptor that recognizes and transports oxidized LIPOPROTEINS and FATTY ACIDS.
A subtype of tetraspanin proteins that play a role in cell adhesion, cell motility, and tumor metastasis. CD9 antigens take part in the process of platelet activation and aggregation, the formation of paranodal junctions in neuronal tissue, and the fusion of sperm with egg.
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
Differentiation antigens expressed on pluripotential hematopoietic cells, most human thymocytes, and a major subset of peripheral blood T-lymphocytes. They have been implicated in integrin-mediated cellular adhesion and as signalling receptors on T-cells.
A sialic acid-rich protein and an integral cell membrane mucin. It plays an important role in activation of T-LYMPHOCYTES.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
A group of three different alpha chains (CD11a, CD11b, CD11c) that are associated with an invariant CD18 beta chain (ANTIGENS, CD18). The three resulting leukocyte-adhesion molecules (RECEPTORS, LEUKOCYTE ADHESION) are LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MACROPHAGE-1 ANTIGEN; and ANTIGEN, P150,95.
A ubiquitously expressed membrane glycoprotein. It interacts with a variety of INTEGRINS and mediates responses to EXTRACELLULAR MATRIX PROTEINS.
Small glycoproteins found on both hematopoietic and non-hematopoietic cells. CD59 restricts the cytolytic activity of homologous complement by binding to C8 and C9 and blocking the assembly of the membrane attack complex. (From Barclay et al., The Leukocyte Antigen FactsBook, 1993, p234)
A transmembrane protein belonging to the tumor necrosis factor superfamily that specifically binds to CD27 ANTIGEN. It is found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; and DENDRITIC CELLS where it plays a role in stimulating the proliferation of CD4-POSITIVE T-LYMPHOCYTES and CD8-POSITIVE T-LYMPHOCYTES.
A ubiquitously expressed complement receptor that binds COMPLEMENT C3B and COMPLEMENT C4B and serves as a cofactor for their inactivation. CD46 also interacts with a wide variety of pathogens and mediates immune response.
A CD antigen that contains a conserved I domain which is involved in ligand binding. When combined with CD18 the two subunits form MACROPHAGE-1 ANTIGEN.
The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer.
Oligosaccharide antigenic determinants found principally on NK cells and T-cells. Their role in the immune response is poorly understood.
Tetraspanin proteins that are involved in a variety of cellular functions including BASEMENT MEMBRANE assembly, and in the formation of a molecular complexes on the surface of LYMPHOCYTES.
A member of the tumor necrosis factor receptor superfamily that is specific for 4-1BB LIGAND. It is found in a variety of immune cell types including activated T-LYMPHOCYTES; NATURAL KILLER CELLS; and DENDRITIC CELLS. Activation of the receptor on T-LYMPHOCYTES plays a role in their expansion, production of cytokines and survival. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
A membrane-bound tumor necrosis family member found primarily on activated T-LYMPHOCYTES that binds specifically to CD30 ANTIGEN. It may play a role in INFLAMMATION and immune regulation.
Cell adhesion molecules present on virtually all monocytes, platelets, and granulocytes. CD31 is highly expressed on endothelial cells and concentrated at the junctions between them.
An integrin alpha subunit of approximately 150-kDa molecular weight. It is expressed at high levels on monocytes and combines with CD18 ANTIGEN to form the cell surface receptor INTEGRIN ALPHAXBETA2. The subunit contains a conserved I-domain which is characteristic of several of alpha integrins.
Tetraspanin proteins found associated with LAMININ-binding INTEGRINS. The CD151 antigens may play a role in the regulation of CELL MOTILITY.
GPI-linked membrane proteins broadly distributed among hematopoietic and non-hematopoietic cells. CD55 prevents the assembly of C3 CONVERTASE or accelerates the disassembly of preformed convertase, thus blocking the formation of the membrane attack complex.
Glycoproteins with a wide distribution on hematopoietic and non-hematopoietic cells and strongly expressed on macrophages. CD58 mediates cell adhesion by binding to CD2; (ANTIGENS, CD2); and this enhances antigen-specific T-cell activation.
Ubiquitously-expressed tetraspanin proteins that are found in late ENDOSOMES and LYSOSOMES and have been implicated in intracellular transport of proteins.
Zinc-binding metalloproteases that are members of the type II integral membrane metalloproteases. They are expressed by GRANULOCYTES; MONOCYTES; and their precursors as well as by various non-hematopoietic cells. They release an N-terminal amino acid from a peptide, amide or arylamide.
An alpha-integrin subunit found on lymphocytes, granulocytes, macrophages and monocytes. It combines with the integrin beta2 subunit (CD18 ANTIGEN) to form LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1.
A widely distributed cell surface transmembrane glycoprotein that stimulates the synthesis of MATRIX METALLOPROTEINASES. It is found at high levels on the surface of malignant NEOPLASMS and may play a role as a mediator of malignant cell behavior.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
A widely expressed transmembrane glycoprotein that functions as a METASTASIS suppressor protein. It is underexpressed in a variety of human NEOPLASMS.
An inhibitory B7 antigen that has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 PROTEIN. CD274 antigen provides negative signals that control and inhibit T-cell responses and is found at higher than normal levels on tumor cells, suggesting its potential role in TUMOR IMMUNE EVASION.
A cell adhesion molecule of the immunoglobulin superfamily that is expressed in ENDOTHELIAL CELLS and is involved in INTERCELLULAR JUNCTIONS.
The altered state of immunologic responsiveness resulting from initial contact with antigen, which enables the individual to produce antibodies more rapidly and in greater quantity in response to secondary antigenic stimulus.
Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Antigens expressed on the cell membrane of T-lymphocytes during differentiation, activation, and normal and neoplastic transformation. Their phenotypic characterization is important in differential diagnosis and studies of thymic ontogeny and T-cell function.
A trisaccharide antigen expressed on glycolipids and many cell-surface glycoproteins. In the blood the antigen is found on the surface of NEUTROPHILS; EOSINOPHILS; and MONOCYTES. In addition, CD15 antigen is a stage-specific embryonic antigen.
A component of the B-cell antigen receptor that is involved in B-cell antigen receptor heavy chain transport to the PLASMA MEMBRANE. It is expressed almost exclusively in B-LYMPHOCYTES and serves as a useful marker for B-cell NEOPLASMS.
CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells.
A heterodimeric protein that is a cell surface antigen associated with lymphocyte activation. The initial characterization of this protein revealed one identifiable heavy chain (ANTIGENS, CD98 HEAVY CHAIN) and an indeterminate smaller light chain. It is now known that a variety of light chain subunits (ANTIGENS, CD98 LIGHT CHAINS) can dimerize with the heavy chain. Depending upon its light chain composition a diverse array of functions can be found for this protein. Functions include: type L amino acid transport, type y+L amino acid transport and regulation of cellular fusion.
Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (ANTIGENS, CD3). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.
A sialomucin protein that functions as a cell adhesion molecule. It is a negative regulator of certain types of HEMATOPOIETIC STEM CELLS.
Antigens expressed primarily on the membranes of living cells during sequential stages of maturation and differentiation. As immunologic markers they have high organ and tissue specificity and are useful as probes in studies of normal cell development as well as neoplastic transformation.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
Tetraspanin proteins found at high levels in cells of the lymphoid-myeloid lineage. CD53 antigens may be involved regulating the differentiation of T-LYMPHOCYTES and the activation of B-LYMPHOCYTES.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
Integrin beta-1 chains which are expressed as heterodimers that are noncovalently associated with specific alpha-chains of the CD49 family (CD49a-f). CD29 is expressed on resting and activated leukocytes and is a marker for all of the very late activation antigens on cells. (from: Barclay et al., The Leukocyte Antigen FactsBook, 1993, p164)
Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner.
A low affinity interleukin-2 receptor subunit that combines with the INTERLEUKIN-2 RECEPTOR BETA SUBUNIT and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN to form a high affinity receptor for INTERLEUKIN-2.
A single, unpaired primary lymphoid organ situated in the MEDIASTINUM, extending superiorly into the neck to the lower edge of the THYROID GLAND and inferiorly to the fourth costal cartilage. It is necessary for normal development of immunologic function early in life. By puberty, it begins to involute and much of the tissue is replaced by fat.
A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.
The number of LYMPHOCYTES per unit volume of BLOOD.
An encapsulated lymphatic organ through which venous blood filters.
Receptors present on activated T-LYMPHOCYTES and B-LYMPHOCYTES that are specific for INTERLEUKIN-2 and play an important role in LYMPHOCYTE ACTIVATION. They are heterotrimeric proteins consisting of the INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT, the INTERLEUKIN-2 RECEPTOR BETA SUBUNIT, and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
Antigenic determinants recognized and bound by the T-cell receptor. Epitopes recognized by the T-cell receptor are often located in the inner, unexposed side of the antigen, and become accessible to the T-cell receptors after proteolytic processing of the antigen.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.
Form of passive immunization where previously sensitized immunologic agents (cells or serum) are transferred to non-immune recipients. When transfer of cells is used as a therapy for the treatment of neoplasms, it is called adoptive immunotherapy (IMMUNOTHERAPY, ADOPTIVE).
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
A subclass of winged helix DNA-binding proteins that share homology with their founding member fork head protein, Drosophila.
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).
Progenitor cells from which all blood cells derive.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
A classification of lymphocytes based on structurally or functionally different populations of cells.
Surface antigens expressed on myeloid cells of the granulocyte-monocyte-histiocyte series during differentiation. Analysis of their reactivity in normal and malignant myelomonocytic cells is useful in identifying and classifying human leukemias and lymphomas.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
The process by which antigen is presented to lymphocytes in a form they can recognize. This is performed by antigen presenting cells (APCs). Some antigens require processing before they can be recognized. Antigen processing consists of ingestion and partial digestion of the antigen by the APC, followed by presentation of fragments on the cell surface. (From Rosen et al., Dictionary of Immunology, 1989)
T-cell receptors composed of CD3-associated alpha and beta polypeptide chains and expressed primarily in CD4+ or CD8+ T-cells. Unlike immunoglobulins, the alpha-beta T-cell receptors recognize antigens only when presented in association with major histocompatibility (MHC) molecules.
Established cell cultures that have the potential to propagate indefinitely.
A membrane-bound or cytosolic enzyme that catalyzes the synthesis of CYCLIC ADP-RIBOSE (cADPR) from nicotinamide adenine dinucleotide (NAD). This enzyme generally catalyzes the hydrolysis of cADPR to ADP-RIBOSE, as well, and sometimes the synthesis of cyclic ADP-ribose 2' phosphate (2'-P-cADPR) from NADP.
Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles.
A technique of culturing mixed cell types in vitro to allow their synergistic or antagonistic interactions, such as on CELL DIFFERENTIATION or APOPTOSIS. Coculture can be of different types of cells, tissues, or organs from normal or disease states.
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
A heterogeneous group of immunocompetent cells that mediate the cellular immune response by processing and presenting antigens to the T-cells. Traditional antigen-presenting cells include MACROPHAGES; DENDRITIC CELLS; LANGERHANS CELLS; and B-LYMPHOCYTES. FOLLICULAR DENDRITIC CELLS are not traditional antigen-presenting cells, but because they hold antigen on their cell surface in the form of IMMUNE COMPLEXES for B-cell recognition they are considered so by some authors.
A class of animal lectins that bind to carbohydrate in a calcium-dependent manner. They share a common carbohydrate-binding domain that is structurally distinct from other classes of lectins.
A soluble factor produced by activated T-LYMPHOCYTES that induces the expression of MHC CLASS II GENES and FC RECEPTORS on B-LYMPHOCYTES and causes their proliferation and differentiation. It also acts on T-lymphocytes, MAST CELLS, and several other hematopoietic lineage cells.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules.
Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumors of B-cell origin.
An element with atomic symbol Cd, atomic number 48, and atomic weight 114. It is a metal and ingestion will lead to CADMIUM POISONING.
The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
Specific molecular sites on the surface of various cells, including B-lymphocytes and macrophages, that combine with IMMUNOGLOBULIN Gs. Three subclasses exist: Fc gamma RI (the CD64 antigen, a low affinity receptor), Fc gamma RII (the CD32 antigen, a high affinity receptor), and Fc gamma RIII (the CD16 antigen, a low affinity receptor).
A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Subset of helper-inducer T-lymphocytes which synthesize and secrete interleukin-2, gamma-interferon, and interleukin-12. Due to their ability to kill antigen-presenting cells and their lymphokine-mediated effector activity, Th1 cells are associated with vigorous delayed-type hypersensitivity reactions.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
A cytokine produced by a variety of cell types, including T-LYMPHOCYTES; MONOCYTES; DENDRITIC CELLS; and EPITHELIAL CELLS that exerts a variety of effects on immunoregulation and INFLAMMATION. Interleukin-10 combines with itself to form a homodimeric molecule that is the biologically active form of the protein.
Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.
An inhibitory T CELL receptor that is closely related to CD28 ANTIGEN. It has specificity for CD80 ANTIGEN and CD86 ANTIGEN and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing PERIPHERAL TOLERANCE.
Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.
Cell adhesion molecule and CD antigen that serves as a homing receptor for lymphocytes to lymph node high endothelial venules.
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen.
A CELL LINE derived from human T-CELL LEUKEMIA and used to determine the mechanism of differential susceptibility to anti-cancer drugs and radiation.
A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed)
A classification of T-lymphocytes, especially into helper/inducer, suppressor/effector, and cytotoxic subsets, based on structurally or functionally different populations of cells.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
A lectin and cell adhesion molecule found in B-LYMPHOCYTES. It interacts with SIALIC ACIDS and mediates signaling from B-CELL ANTIGEN RECEPTORS.
The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.
A transmembrane protein belonging to the tumor necrosis factor superfamily that was originally discovered on cells of the lymphoid-myeloid lineage, including activated T-LYMPHOCYTES and NATURAL KILLER CELLS. It plays an important role in immune homeostasis and cell-mediated toxicity by binding to the FAS RECEPTOR and triggering APOPTOSIS.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery.
Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.
An albumin obtained from the white of eggs. It is a member of the serpin superfamily.
Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behavior of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere.
Subpopulation of CD4+ lymphocytes that cooperate with other lymphocytes (either T or B) to initiate a variety of immune functions. For example, helper-inducer T-cells cooperate with B-cells to produce antibodies to thymus-dependent antigens and with other subpopulations of T-cells to initiate a variety of cell-mediated immune functions.
Adherence of cells to surfaces or to other cells.
Reproducible depletion of CD4+ lymphocytes below 300 per cubic millimeter in the absence of HIV infection or other known causes of immunodeficiency. This is a rare, heterogeneous syndrome and does not appear to be caused by a transmissible agent.
The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.)
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
Subset of helper-inducer T-lymphocytes which synthesize and secrete the interleukins IL-4, IL-5, IL-6, and IL-10. These cytokines influence B-cell development and antibody production as well as augmenting humoral responses.
A calcium-dependent pore-forming protein synthesized in cytolytic LYMPHOCYTES and sequestered in secretory granules. Upon immunological reaction between a cytolytic lymphocyte and a target cell, perforin is released at the plasma membrane and polymerizes into transmembrane tubules (forming pores) which lead to death of a target cell.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
A low affinity interleukin-7 receptor subunit that combines with the INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT to form a high affinity receptor for INTERLEUKIN-7.
An adhesion-promoting leukocyte surface membrane heterodimer. The alpha subunit consists of the CD11b ANTIGEN and the beta subunit the CD18 ANTIGEN. The antigen, which is an integrin, functions both as a receptor for complement 3 and in cell-cell and cell-substrate adhesive interactions.
A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS.
A 67-kDa sialic acid binding lectin that is specific for MYELOID CELLS and MONOCYTE-MACROPHAGE PRECURSOR CELLS. This protein is the smallest siglec subtype and contains a single immunoglobulin C2-set domain. It may play a role in intracellular signaling via its interaction with SHP-1 PROTEIN-TYROSINE PHOSPHATASE and SHP-2 PROTEIN-TYROSINE PHOSPHATASE.
Elements of limited time intervals, contributing to particular results or situations.
Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression.
The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments.
A strain of non-obese diabetic mice developed in Japan that has been widely studied as a model for T-cell-dependent autoimmune insulin-dependent diabetes mellitus in which insulitis is a major histopathologic feature, and in which genetic susceptibility is strongly MHC-linked.
Antibodies that inhibit the reaction between ANTIGEN and other antibodies or sensitized T-LYMPHOCYTES (e.g., antibodies of the IMMUNOGLOBULIN G class that compete with IGE antibodies for antigen, thereby blocking an allergic response). Blocking antibodies that bind tumors and prevent destruction of tumor cells by CYTOTOXIC T-LYMPHOCYTES have also been called enhancing antibodies. (Rosen et al., Dictionary of Immunology, 1989)
Proteins prepared by recombinant DNA technology.
The developmental history of specific differentiated cell types as traced back to the original STEM CELLS in the embryo.
Any of several ways in which living cells of an organism communicate with one another, whether by direct contact between cells or by means of chemical signals carried by neurotransmitter substances, hormones, and cyclic AMP.
A cell line derived from cultured tumor cells.
Membrane glycoproteins consisting of an alpha subunit and a BETA 2-MICROGLOBULIN beta subunit. In humans, highly polymorphic genes on CHROMOSOME 6 encode the alpha subunits of class I antigens and play an important role in determining the serological specificity of the surface antigen. Class I antigens are found on most nucleated cells and are generally detected by their reactivity with alloantisera. These antigens are recognized during GRAFT REJECTION and restrict cell-mediated lysis of virus-infected cells.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
A heterodimeric cytokine that plays a role in innate and adaptive immune responses. Interleukin-12 is a 70 kDa protein that is composed of covalently linked 40 kDa and 35 kDa subunits. It is produced by DENDRITIC CELLS; MACROPHAGES and a variety of other immune cells and plays a role in the stimulation of INTERFERON-GAMMA production by T-LYMPHOCYTES and NATURAL KILLER CELLS.
Reduction in the number of lymphocytes.
Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors.
Cytokine that stimulates the proliferation of T-LYMPHOCYTES and shares biological activities with IL-2. IL-15 also can induce proliferation and differentiation of B-LYMPHOCYTES.
Molecule composed of the non-covalent association of the T-cell antigen receptor (RECEPTORS, ANTIGEN, T-CELL) with the CD3 complex (ANTIGENS, CD3). This association is required for the surface expression and function of both components. The molecule consists of up to seven chains: either the alpha/beta or gamma/delta chains of the T-cell receptor, and four or five chains in the CD3 complex.
A classification of B-lymphocytes based on structurally or functionally different populations of cells.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.
Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
Cell surface glycoproteins on lymphocytes and other leukocytes that mediate adhesion to specialized blood vessels called high endothelial venules. Several different classes of lymphocyte homing receptors have been identified, and they appear to target different surface molecules (addressins) on high endothelial venules in different tissues. The adhesion plays a crucial role in the trafficking of lymphocytes.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Sites on an antigen that interact with specific antibodies.
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
A transmembrane glycoprotein subunit that can dimerize with a variety of light chain subunits (ANTIGENS, CD98 LIGHT CHAINS). This protein subunit serves a diverse array of functions including amino acid transport and cell fusion. Its function is altered depending which of the light chain subunits it interacts with.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Proteins secreted from an organism which form membrane-spanning pores in target cells to destroy them. This is in contrast to PORINS and MEMBRANE TRANSPORT PROTEINS that function within the synthesizing organism and COMPLEMENT immune proteins. These pore forming cytotoxic proteins are a form of primitive cellular defense which are also found in human LYMPHOCYTES.
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
A family of serine endopeptidases found in the SECRETORY GRANULES of LEUKOCYTES such as CYTOTOXIC T-LYMPHOCYTES and NATURAL KILLER CELLS. When secreted into the intercellular space granzymes act to eliminate transformed and virus-infected host cells.
Functional inactivation of T- or B-lymphocytes rendering them incapable of eliciting an immune response to antigen. This occurs through different mechanisms in the two kinds of lymphocytes and can contribute to SELF TOLERANCE.
Substances that are recognized by the immune system and induce an immune reaction.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
This enzyme is a lymphoid-specific src family tyrosine kinase that is critical for T-cell development and activation. Lck is associated with the cytoplasmic domains of CD4, CD8 and the beta-chain of the IL-2 receptor, and is thought to be involved in the earliest steps of TCR-mediated T-cell activation.
Specialized tissues that are components of the lymphatic system. They provide fixed locations within the body where a variety of LYMPHOCYTES can form, mature and multiply. The lymphoid tissues are connected by a network of LYMPHATIC VESSELS.
A subclass of lipid-linked proteins that contain a GLYCOSYLPHOSPHATIDYLINOSITOL LINKAGE which holds them to the CELL MEMBRANE.
A calcium-activated enzyme that catalyzes the hydrolysis of ATP to yield AMP and orthophosphate. It can also act on ADP and other nucleoside triphosphates and diphosphates. EC 3.6.1.5.
A subclass of NK cell lectin-like receptors that includes both inhibitory and stimulatory members.
A cytokine produced by bone marrow stromal cells that promotes the growth of B-LYMPHOCYTE precursors and is co-mitogenic with INTERLEUKIN-2 for mature T-LYMPHOCYTE activation.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120 kDa and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably T4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV.
Antigens that exist in alternative (allelic) forms in a single species. When an isoantigen is encountered by species members who lack it, an immune response is induced. Typical isoantigens are the BLOOD GROUP ANTIGENS.
Cell surface glycoproteins that bind to chemokines and thus mediate the migration of pro-inflammatory molecules. The receptors are members of the seven-transmembrane G protein-coupled receptor family. Like the CHEMOKINES themselves, the receptors can be divided into at least three structural branches: CR, CCR, and CXCR, according to variations in a shared cysteine motif.
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
A round-to-oval mass of lymphoid tissue embedded in the lateral wall of the PHARYNX. There is one on each side of the oropharynx in the fauces between the anterior and posterior pillars of the SOFT PALATE.

Fas and Fas ligand interaction induces apoptosis in inflammatory myopathies: CD4+ T cells cause muscle cell injury directly in polymyositis. (1/810)

OBJECTIVE: To investigate the involvement of the Fas/Fas ligand (Fas/FasL) system in the inflammatory myopathies. METHODS: Frozen muscle sections obtained from 7 patients with polymyositis (PM), 4 patients with dermatomyositis (DM), and 3 controls were studied by immunochemistry. Apoptosis was detected by DNA electrophoresis and in situ labeling using the TUNEL method. RESULTS: Fas was detected on muscle fibers and infiltrating mononuclear cells (MNC) in 6 PM patients and 2 DM patients. FasL was expressed mainly on CD4+ T cells and some CD8+ T cells, and on macrophages surrounding Fas-positive muscles in 4 PM patients and 1 DM patient. In 3 of the 5 patients with FasL-positive MNC, the TUNEL method showed that both invaded myonuclei and MNC underwent apoptosis. Chromosomal DNA from the muscle tissue of these patients showed ladder formation. CONCLUSION: Fas/FasL is involved in muscle cell apoptosis in at least 2 of the inflammatory myopathies, PM and DM. Although CD8+-mediated cytotoxicity is thought to be the main mechanism of muscle injury in PM, our data suggest that CD4+ T cells also directly cause muscle cell damage.  (+info)

Dopamine beta-hydroxylase deficiency impairs cellular immunity. (2/810)

Norepinephrine, released from sympathetic neurons, and epinephrine, released from the adrenal medulla, participate in a number of physiological processes including those that facilitate adaptation to stressful conditions. The thymus, spleen, and lymph nodes are richly innervated by the sympathetic nervous system, and catecholamines are thought to modulate the immune response. However, the importance of this modulatory role in vivo remains uncertain. We addressed this question genetically by using mice that lack dopamine beta-hydroxylase (dbh-/- mice). dbh-/- mice cannot produce norepinephrine or epinephrine, but produce dopamine instead. When housed in specific pathogen-free conditions, dbh-/- mice had normal numbers of blood leukocytes, and normal T and B cell development and in vitro function. However, when challenged in vivo by infection with the intracellular pathogens Listeria monocytogenes or Mycobacterium tuberculosis, dbh-/- mice were more susceptible to infection, exhibited extreme thymic involution, and had impaired T cell function, including Th1 cytokine production. When immunized with trinitrophenyl-keyhole limpet hemocyanin, dbh-/- mice produced less Th1 cytokine-dependent-IgG2a antitrinitrophenyl antibody. These results indicate that physiological catecholamine production is not required for normal development of the immune system, but plays an important role in the modulation of T cell-mediated immunity to infection and immunization.  (+info)

HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines. (3/810)

Vaccine strategies designed to elicit strong cell-mediated immune responses to HIV Ags are likely to lead to protective immunity against HIV infection. Dendritic cells (DC) are the most potent APCs capable of priming both MHC class I- and II-restricted, Ag-specific T cell responses. Utilizing a system in which cultured DC from HIV-seronegative donors were used as APC to present HIV-1 Ags to autologous T cells in vitro, the strength and specificity of primary HIV-specific CTL responses generated to exogenous HIV-1 Nef protein as well as intracellularly expressed nef transgene product were investigated. DC expressing the nef gene were able to stimulate Nef-specific CTL, with T cells from several donors recognizing more than one epitope restricted by a single HLA molecule. Primary Nef-specific CTL responses were also generated in vitro using DC pulsed with Nef protein. T cells primed with Nef-expressing DC (via protein or transgene) were able to lyse MHC class I-matched target cells pulsed with defined Nef epitope peptides as well as newly identified peptide epitopes. The addition of Th1-biasing cytokines IL-12 or IFN-alpha, during priming with Nef-expressing DC, enhanced the Nef-specific CTL responses generated using either Ag-loading approach. These results suggest that this in vitro vaccine model may be useful in identifying immunogenic epitopes as vaccine targets and in evaluating the effects of cytokines and other adjuvants on Ag-specific T cell induction. Successful approaches may provide information important to the development of prophylactic HIV vaccines and are envisioned to be readily translated into clinical DC-based therapeutic vaccines for HIV-1.  (+info)

Secretion of beta-chemokines by bronchoalveolar lavage cells during primary infection of macaques inoculated with attenuated nef-deleted or pathogenic simian immunodeficiency virus strain mac251. (4/810)

Primary infection of macaques with simian immunodeficiency virus (SIV) as a model of human immunodeficiency virus (HIV) infection represents a unique opportunity to investigate early lentivirus-host interactions. In order to gain insight into immunopathogenic events taking place in the lung during lentiviral infection, we analysed lymphocyte expansion in the lung and chemokine secretion by mononuclear cells obtained by bronchoalveolar lavage (BALMCs) during primary infection by a pathogenic and a non-pathogenic SIV. Two groups of cynomolgus macaques were inoculated intravenously with a fully pathogenic isolate of SIVmac251 or with an attenuated, nef-deleted, molecular clone of SIVmac251. Spontaneous MIP-1alpha, MIP-1beta and RANTES production was assessed by ELISA in supernatants of short-term cultured BALMCs. Kinetics of haematological, virological and immunological parameters were investigated simultaneously. All 11 inoculated animals became infected. Monkeys inoculated with the nef-deleted SIV clone exhibited a significantly reduced plasma virus load and a less pronounced accumulation of lymphocytes in the lung compared to monkeys infected with the pathogenic SIVmac251 isolate. Compared to pre-infection levels, we observed an increase in the levels of RANTES, MIP1-alpha and MIP1-beta production in the two groups of monkeys, by the time of peak viraemia. Strikingly, a greater enhancement of RANTES and MIP-1alpha production was detected in monkeys infected with the attenuated virus. Given the potential influence of beta-chemokines on the immune response and virus replication, such results suggest that RANTES, MIP1-alpha and MIP1-beta could contribute to the singular features of the immune response elicited during infection of macaques with an attenuated SIV.  (+info)

Phenotypic analysis of lymphocytes and monocytes/macrophages in peripheral blood and bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. (5/810)

BACKGROUND: The granulomatous inflammation in sarcoidosis is driven by the interplay between T cells and macrophages. To gain a better understanding of this process the expression by these cells of cell surface activation markers, co-stimulatory molecules, and adhesion molecules was analysed. METHODS: CD4+ and CD8+ T lymphocytes from peripheral blood (PBL) or bronchoalveolar lavage (BAL) fluid, as well as paired peripheral blood monocytes and alveolar macrophages from 27 patients with sarcoidosis were analysed by flow cytometry. RESULTS: CD26, CD54, CD69, CD95, and gp240 were all overexpressed in T cells from BAL fluid compared with those from PBL in both the CD4+ and CD8+ subsets, while CD57 was overexpressed only in BAL CD4+ cells. In contrast, CD28 tended to be underexpressed in the BAL T cells. Monocyte/macrophage markers included CD11a, CD11b, CD11c, CD14, CD16, CD54, CD71, CD80 and CD86 and HLA class II. CD11a expression in alveolar macrophages (and peripheral blood monocytes) was increased in patients with active disease and correlated positively with the percentage of BAL lymphocytes. Expression of CD80 in macrophages correlated with the BAL CD4/CD8 ratio. CONCLUSIONS: Our data indicate substantial activation of both CD4+ and CD8+ lung T cells in sarcoidosis. There were also increased numbers of BAL lymphocytes whose phenotypic characteristics have earlier been associated with clonally expanded, replicatively senescent cells of the Th1 type.  (+info)

Postthymic development of CD28-CD8+ T cell subset: age-associated expansion and shift from memory to naive phenotype. (6/810)

During human aging, one of the major changes in the T cell repertoire is a dramatic expansion of T cells with the atypical CD28-CD8+ phenotype. In this study, we show that this increase is a consequence not only of an expansion in the CD28-CD8+ population but also of a decrease in the number of CD28+CD8+ T cells. The decrease in circulating CD28+CD8+ T cells is dramatically accelerated after the age of 50 and is not accompanied by an equivalent reduction in the CD28+CD8+ subset. Our findings confirm that aging leads to an accumulation of CD45RO+ T cells within the CD28+CD8+ subset as previously observed. Surprisingly, we found an increase in CD45RA+ expression with age in the CD28-CD8+ subset. Immune-phenotyping for activation markers, measurement of telomere DNA content, and cytokine production analysis indicate that the large majority of CD28-CD8+ T cells are Ag-experienced, despite their CD45RA+ phenotype. Our study further demonstrates that the poor proliferative response displayed by CD28-CD8+ T cells is not a consequence of telomere shortening. Also, analysis of cytokine production at the single cell level revealed that the proportions of IFN-gamma +, IL-4+, and IL-10+ T cells are considerably higher among the CD28-CD8+ than the CD28+CD8+ subset. In summary, these data explain the presence of CD45RA+ T cells in the elderly, shed light on the phylogenetic origin of CD28-CD8+ T cells, and suggest a role for these cells in the immune senescence process.  (+info)

The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients. (7/810)

We investigated the potential existence of differences in the distribution of T-lymphocyte subsets and in the proliferative response of these CD2+ cells to polyclonal mitogens in patients with transitional cell bladder carcinoma (SBTCC) treated with prophylactic intracavitary instillations of bacillus Calmette-Guerin (BCG) according to their clinical response to this treatment. Before BCG treatment, different subset distribution (CD8+ and CD3+ CD56+), activation antigen expression (CD3+ HLA- DR+) and proliferative response to mitogenic signals were found in CD2+ cells from SBTCC patients prophylactically treated with BCG who remained free of disease or those who had recurrence of tumour. Otherwise, the prophylactic intracavitary BCG instillations in SBTCC patients are associated with a transitory variation of T-lymphocyte subset distribution (CD4 and CD8) and activation antigens expression (CD25).  (+info)

T-cell insulitis found in anti-GAD65+ diabetes with residual beta-cell function. A case report. (8/810)

CASE HISTORY: We recently encountered a 65-year-old anti-GAD+ diabetic woman with residual beta-cell function who was proved to have T-cell insulitis. The proportion of CD4+ and CD8+ cells varied among individual islets, although CD4+ cells tended to be the predominant T-cell type in the islets examined. All of the islets examined still contained insulin, suggesting that beta-cell mass may have been preserved. DISCUSSION: It is well known that lymphocytic infiltration of pancreatic islets, a condition referred to as "insulitis," is seen in acute-onset type 1 diabetes at autopsy and in biopsy specimens. However, there have been no proven cases of insulitis in type 1 diabetes with residual beta-cell function. We believe that this is the first type 1 diabetic patient with residual beta-cell function who was proven to have T-cell insulitis. This novel evidence will contribute to the proper classification and treatment of diabetes and to a better understanding of the pathophysiology of type 1 diabetes.  (+info)

HIV (human immunodeficiency virus) infection is a condition in which the body is infected with HIV, a type of retrovirus that attacks the body's immune system. HIV infection can lead to AIDS (acquired immunodeficiency syndrome), a condition in which the immune system is severely damaged and the body is unable to fight off infections and diseases.

There are several ways that HIV can be transmitted, including:

1. Sexual contact with an infected person
2. Sharing of needles or other drug paraphernalia with an infected person
3. Mother-to-child transmission during pregnancy, childbirth, or breastfeeding
4. Blood transfusions ( although this is rare in developed countries due to screening processes)
5. Organ transplantation (again, rare)

The symptoms of HIV infection can be mild at first and may not appear until several years after infection. These symptoms can include:

1. Fever
2. Fatigue
3. Swollen glands in the neck, armpits, and groin
4. Rash
5. Muscle aches and joint pain
6. Night sweats
7. Diarrhea
8. Weight loss

If left untreated, HIV infection can progress to AIDS, which is a life-threatening condition that can cause a wide range of symptoms, including:

1. Opportunistic infections (such as pneumocystis pneumonia)
2. Cancer (such as Kaposi's sarcoma)
3. Wasting syndrome
4. Neurological problems (such as dementia and seizures)

HIV infection is diagnosed through a combination of blood tests and physical examination. Treatment typically involves antiretroviral therapy (ART), which is a combination of medications that work together to suppress the virus and slow the progression of the disease.

Prevention methods for HIV infection include:

1. Safe sex practices, such as using condoms and dental dams
2. Avoiding sharing needles or other drug-injecting equipment
3. Avoiding mother-to-child transmission during pregnancy, childbirth, or breastfeeding
4. Post-exposure prophylaxis (PEP), which is a short-term treatment that can prevent infection after potential exposure to the virus
5. Pre-exposure prophylaxis (PrEP), which is a daily medication that can prevent infection in people who are at high risk of being exposed to the virus.

It's important to note that HIV infection is manageable with proper treatment and care, and that people living with HIV can lead long and healthy lives. However, it's important to be aware of the risks and take steps to prevent transmission.

There are several possible causes of lymphopenia, including:

1. Viral infections: Many viral infections can cause lymphopenia, such as HIV/AIDS, hepatitis B and C, and influenza.
2. Bacterial infections: Some bacterial infections, such as tuberculosis and leprosy, can also cause lymphopenia.
3. Cancer: Certain types of cancer, such as Hodgkin's disease and non-Hodgkin's lymphoma, can cause lymphopenia by destroying lymphocytes.
4. Autoimmune disorders: Autoimmune disorders, such as rheumatoid arthritis and lupus, can cause lymphopenia by attacking the body's own tissues, including lymphocytes.
5. Radiation therapy: Radiation therapy can destroy lymphocytes and cause lymphopenia.
6. Medications: Certain medications, such as chemotherapy drugs and antibiotics, can cause lymphopenia as a side effect.
7. Genetic disorders: Some genetic disorders, such as X-linked lymphoproliferative disease, can cause lymphopenia by affecting the development or function of lymphocytes.

Symptoms of lymphopenia can include recurring infections, fatigue, and swollen lymph nodes. Treatment of lymphopenia depends on the underlying cause and may involve antibiotics, antiviral medications, or immunoglobulin replacement therapy. In some cases, a bone marrow transplant may be necessary.

Overall, lymphopenia is a condition that can have a significant impact on quality of life, and it is important to seek medical attention if symptoms persist or worsen over time. With proper diagnosis and treatment, many people with lymphopenia can experience improved health outcomes and a better quality of life.

1) They share similarities with humans: Many animal species share similar biological and physiological characteristics with humans, making them useful for studying human diseases. For example, mice and rats are often used to study diseases such as diabetes, heart disease, and cancer because they have similar metabolic and cardiovascular systems to humans.

2) They can be genetically manipulated: Animal disease models can be genetically engineered to develop specific diseases or to model human genetic disorders. This allows researchers to study the progression of the disease and test potential treatments in a controlled environment.

3) They can be used to test drugs and therapies: Before new drugs or therapies are tested in humans, they are often first tested in animal models of disease. This allows researchers to assess the safety and efficacy of the treatment before moving on to human clinical trials.

4) They can provide insights into disease mechanisms: Studying disease models in animals can provide valuable insights into the underlying mechanisms of a particular disease. This information can then be used to develop new treatments or improve existing ones.

5) Reduces the need for human testing: Using animal disease models reduces the need for human testing, which can be time-consuming, expensive, and ethically challenging. However, it is important to note that animal models are not perfect substitutes for human subjects, and results obtained from animal studies may not always translate to humans.

6) They can be used to study infectious diseases: Animal disease models can be used to study infectious diseases such as HIV, TB, and malaria. These models allow researchers to understand how the disease is transmitted, how it progresses, and how it responds to treatment.

7) They can be used to study complex diseases: Animal disease models can be used to study complex diseases such as cancer, diabetes, and heart disease. These models allow researchers to understand the underlying mechanisms of the disease and test potential treatments.

8) They are cost-effective: Animal disease models are often less expensive than human clinical trials, making them a cost-effective way to conduct research.

9) They can be used to study drug delivery: Animal disease models can be used to study drug delivery and pharmacokinetics, which is important for developing new drugs and drug delivery systems.

10) They can be used to study aging: Animal disease models can be used to study the aging process and age-related diseases such as Alzheimer's and Parkinson's. This allows researchers to understand how aging contributes to disease and develop potential treatments.

There are several key features of inflammation:

1. Increased blood flow: Blood vessels in the affected area dilate, allowing more blood to flow into the tissue and bringing with it immune cells, nutrients, and other signaling molecules.
2. Leukocyte migration: White blood cells, such as neutrophils and monocytes, migrate towards the site of inflammation in response to chemical signals.
3. Release of mediators: Inflammatory mediators, such as cytokines and chemokines, are released by immune cells and other cells in the affected tissue. These molecules help to coordinate the immune response and attract more immune cells to the site of inflammation.
4. Activation of immune cells: Immune cells, such as macrophages and T cells, become activated and start to phagocytose (engulf) pathogens or damaged tissue.
5. Increased heat production: Inflammation can cause an increase in metabolic activity in the affected tissue, leading to increased heat production.
6. Redness and swelling: Increased blood flow and leakiness of blood vessels can cause redness and swelling in the affected area.
7. Pain: Inflammation can cause pain through the activation of nociceptors (pain-sensing neurons) and the release of pro-inflammatory mediators.

Inflammation can be acute or chronic. Acute inflammation is a short-term response to injury or infection, which helps to resolve the issue quickly. Chronic inflammation is a long-term response that can cause ongoing damage and diseases such as arthritis, asthma, and cancer.

There are several types of inflammation, including:

1. Acute inflammation: A short-term response to injury or infection.
2. Chronic inflammation: A long-term response that can cause ongoing damage and diseases.
3. Autoimmune inflammation: An inappropriate immune response against the body's own tissues.
4. Allergic inflammation: An immune response to a harmless substance, such as pollen or dust mites.
5. Parasitic inflammation: An immune response to parasites, such as worms or fungi.
6. Bacterial inflammation: An immune response to bacteria.
7. Viral inflammation: An immune response to viruses.
8. Fungal inflammation: An immune response to fungi.

There are several ways to reduce inflammation, including:

1. Medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying anti-rheumatic drugs (DMARDs).
2. Lifestyle changes, such as a healthy diet, regular exercise, stress management, and getting enough sleep.
3. Alternative therapies, such as acupuncture, herbal supplements, and mind-body practices.
4. Addressing underlying conditions, such as hormonal imbalances, gut health issues, and chronic infections.
5. Using anti-inflammatory compounds found in certain foods, such as omega-3 fatty acids, turmeric, and ginger.

It's important to note that chronic inflammation can lead to a range of health problems, including:

1. Arthritis
2. Diabetes
3. Heart disease
4. Cancer
5. Alzheimer's disease
6. Parkinson's disease
7. Autoimmune disorders, such as lupus and rheumatoid arthritis.

Therefore, it's important to manage inflammation effectively to prevent these complications and improve overall health and well-being.

Examples of autoimmune diseases include:

1. Rheumatoid arthritis (RA): A condition where the immune system attacks the joints, leading to inflammation, pain, and joint damage.
2. Lupus: A condition where the immune system attacks various body parts, including the skin, joints, and organs.
3. Hashimoto's thyroiditis: A condition where the immune system attacks the thyroid gland, leading to hypothyroidism.
4. Multiple sclerosis (MS): A condition where the immune system attacks the protective covering of nerve fibers in the central nervous system, leading to communication problems between the brain and the rest of the body.
5. Type 1 diabetes: A condition where the immune system attacks the insulin-producing cells in the pancreas, leading to high blood sugar levels.
6. Guillain-Barré syndrome: A condition where the immune system attacks the nerves, leading to muscle weakness and paralysis.
7. Psoriasis: A condition where the immune system attacks the skin, leading to red, scaly patches.
8. Crohn's disease and ulcerative colitis: Conditions where the immune system attacks the digestive tract, leading to inflammation and damage to the gut.
9. Sjögren's syndrome: A condition where the immune system attacks the glands that produce tears and saliva, leading to dry eyes and mouth.
10. Vasculitis: A condition where the immune system attacks the blood vessels, leading to inflammation and damage to the blood vessels.

The symptoms of autoimmune diseases vary depending on the specific disease and the organs or tissues affected. Common symptoms include fatigue, fever, joint pain, skin rashes, and swollen lymph nodes. Treatment for autoimmune diseases typically involves medication to suppress the immune system and reduce inflammation, as well as lifestyle changes such as dietary changes and stress management techniques.

In LLCB, the B cells undergo a mutation that causes them to become cancerous and multiply rapidly. This can lead to an overproduction of these cells in the bone marrow, causing the bone marrow to become crowded and unable to produce healthy red blood cells, platelets, and white blood cells.

LLCB is typically a slow-growing cancer, and it can take years for symptoms to develop. However, as the cancer progresses, it can lead to a range of symptoms including fatigue, weakness, weight loss, fever, night sweats, and swollen lymph nodes.

LLCB is typically diagnosed through a combination of physical examination, blood tests, bone marrow biopsy, and imaging studies such as X-rays or CT scans. Treatment options for LLCB include chemotherapy, radiation therapy, and in some cases, stem cell transplantation.

Overall, while LLCB is a serious condition, it is typically slow-growing and can be managed with appropriate treatment. With current treatments, many people with LLCB can achieve long-term remission and a good quality of life.

There are several subtypes of lymphoma, B-cell, including:

1. Diffuse large B-cell lymphoma (DLBCL): This is the most common type of B-cell lymphoma and typically affects older adults.
2. Follicular lymphoma: This type of lymphoma grows slowly and often does not require treatment for several years.
3. Marginal zone lymphoma: This type of lymphoma develops in the marginal zone of the spleen or other lymphoid tissues.
4. Hodgkin lymphoma: This is a type of B-cell lymphoma that is characterized by the presence of Reed-Sternberg cells, which are abnormal cells that can be identified under a microscope.

The symptoms of lymphoma, B-cell can vary depending on the subtype and the location of the tumor. Common symptoms include swollen lymph nodes, fatigue, fever, night sweats, and weight loss.

Treatment for lymphoma, B-cell usually involves chemotherapy, which is a type of cancer treatment that uses drugs to kill cancer cells. Radiation therapy may also be used in some cases. In some cases, bone marrow or stem cell transplantation may be recommended.

Prognosis for lymphoma, B-cell depends on the subtype and the stage of the disease at the time of diagnosis. In general, the prognosis is good for patients with early-stage disease, but the cancer can be more difficult to treat if it has spread to other parts of the body.

Prevention of lymphoma, B-cell is not possible, as the exact cause of the disease is not known. However, avoiding exposure to certain risk factors, such as viral infections and pesticides, may help reduce the risk of developing the disease. Early detection and treatment can also improve outcomes for patients with lymphoma, B-cell.

Lymphoma, B-cell is a type of cancer that affects the immune system and can be treated with chemotherapy and other therapies. The prognosis varies depending on the subtype and stage of the disease at diagnosis. Prevention is not possible, but early detection and treatment can improve outcomes for patients with this condition.

Disease progression can be classified into several types based on the pattern of worsening:

1. Chronic progressive disease: In this type, the disease worsens steadily over time, with a gradual increase in symptoms and decline in function. Examples include rheumatoid arthritis, osteoarthritis, and Parkinson's disease.
2. Acute progressive disease: This type of disease worsens rapidly over a short period, often followed by periods of stability. Examples include sepsis, acute myocardial infarction (heart attack), and stroke.
3. Cyclical disease: In this type, the disease follows a cycle of worsening and improvement, with periodic exacerbations and remissions. Examples include multiple sclerosis, lupus, and rheumatoid arthritis.
4. Recurrent disease: This type is characterized by episodes of worsening followed by periods of recovery. Examples include migraine headaches, asthma, and appendicitis.
5. Catastrophic disease: In this type, the disease progresses rapidly and unpredictably, with a poor prognosis. Examples include cancer, AIDS, and organ failure.

Disease progression can be influenced by various factors, including:

1. Genetics: Some diseases are inherited and may have a predetermined course of progression.
2. Lifestyle: Factors such as smoking, lack of exercise, and poor diet can contribute to disease progression.
3. Environmental factors: Exposure to toxins, allergens, and other environmental stressors can influence disease progression.
4. Medical treatment: The effectiveness of medical treatment can impact disease progression, either by slowing or halting the disease process or by causing unintended side effects.
5. Co-morbidities: The presence of multiple diseases or conditions can interact and affect each other's progression.

Understanding the type and factors influencing disease progression is essential for developing effective treatment plans and improving patient outcomes.

Examples of acute diseases include:

1. Common cold and flu
2. Pneumonia and bronchitis
3. Appendicitis and other abdominal emergencies
4. Heart attacks and strokes
5. Asthma attacks and allergic reactions
6. Skin infections and cellulitis
7. Urinary tract infections
8. Sinusitis and meningitis
9. Gastroenteritis and food poisoning
10. Sprains, strains, and fractures.

Acute diseases can be treated effectively with antibiotics, medications, or other therapies. However, if left untreated, they can lead to chronic conditions or complications that may require long-term care. Therefore, it is important to seek medical attention promptly if symptoms persist or worsen over time.

Crohn disease can occur in any part of the GI tract, from the mouth to the anus, but it most commonly affects the ileum (the last portion of the small intestine) and the colon. The inflammation caused by Crohn disease can lead to the formation of scar tissue, which can cause narrowing or blockages in the intestines. This can lead to complications such as bowel obstruction or abscesses.

The exact cause of Crohn disease is not known, but it is believed to be an autoimmune disorder, meaning that the immune system mistakenly attacks healthy tissue in the GI tract. Genetic factors and environmental triggers such as smoking and diet also play a role in the development of the disease.

There is no cure for Crohn disease, but various treatments can help manage symptoms and prevent complications. These may include medications such as anti-inflammatory drugs, immunosuppressants, and biologics, as well as lifestyle changes such as dietary modifications and stress management techniques. In severe cases, surgery may be necessary to remove damaged portions of the GI tract.

Crohn disease can have a significant impact on quality of life, and it is important for individuals with the condition to work closely with their healthcare provider to manage their symptoms and prevent complications. With proper treatment and self-care, many people with Crohn disease are able to lead active and fulfilling lives.

The symptoms of LCM can vary depending on the severity of the infection, but they typically include fever, headache, neck stiffness, and sensitivity to light. In severe cases, LCM can cause meningitis, encephalitis (inflammation of the brain), and even death.

The diagnosis of LCM is based on a combination of clinical symptoms, laboratory tests, and imaging studies such as MRI or CT scans. Laboratory tests may include blood tests to detect the presence of antibodies against the virus, as well as tests to assess liver function and other organ systems.

Treatment of LCM typically involves supportive care, such as intravenous fluids, oxygen therapy, and pain management. Antiviral medications may also be used in some cases. In severe cases, hospitalization may be required to monitor and treat the patient.

Prevention of LCM primarily involves avoiding contact with infected rodents, particularly during pregnancy and childhood when the risk of infection is higher. Good hygiene practices, such as frequent handwashing, can also help reduce the risk of transmission. Vaccines are not available for LCM, but research is ongoing to develop one.

The prognosis for LCM varies depending on the severity of the infection and the promptness and effectiveness of treatment. In general, the outcome is good for patients with mild symptoms, but those with severe infections may experience long-term neurological problems or death.

The symptoms of AIDS can vary depending on the individual and the stage of the disease. Common symptoms include:

1. Fever
2. Fatigue
3. Swollen glands
4. Rash
5. Muscle aches and joint pain
6. Night sweats
7. Diarrhea
8. Weight loss
9. Memory loss and other neurological problems
10. Cancer and other opportunistic infections.

AIDS is diagnosed through blood tests that detect the presence of HIV antibodies or the virus itself. There is no cure for AIDS, but antiretroviral therapy (ART) can help manage the symptoms and slow the progression of the disease. Prevention methods include using condoms, pre-exposure prophylaxis (PrEP), and avoiding sharing needles or other injection equipment.

In summary, Acquired Immunodeficiency Syndrome (AIDS) is a severe and life-threatening condition caused by the Human Immunodeficiency Virus (HIV). It is characterized by a severely weakened immune system, which makes it difficult to fight off infections and diseases. While there is no cure for AIDS, antiretroviral therapy can help manage the symptoms and slow the progression of the disease. Prevention methods include using condoms, pre-exposure prophylaxis, and avoiding sharing needles or other injection equipment.

SAIDS was first identified in the 1980s in monkeys that were being used in research laboratories, and it has since been studied extensively as a model for HIV/AIDS research. Like HIV/AIDS, SAIDS is caused by the transmission of a virus from one animal to another through contact with infected bodily fluids, such as blood or semen.

The symptoms of SAIDS are similar to those of HIV/AIDS and include fever, fatigue, weight loss, and opportunistic infections. As the disease progresses, animals may also experience neurological symptoms, such as seizures and difficulty coordinating movements.

There is currently no cure for SAIDS, and treatment is focused on managing the symptoms and preventing complications. Research into the disease has led to a greater understanding of the immunopathogenesis of HIV/AIDS and has contributed to the development of new therapies for the disease.

SAIDS is important in medical research because it provides a valuable model for studying the immunopathogenesis of HIV/AIDS and for testing new therapies and vaccines. It also serves as a reminder of the importance of strict safety protocols when working with infectious agents, particularly in laboratory settings.

The symptoms of listeriosis can vary depending on the severity of the infection and the individual's overall health. Mild cases may present with flu-like symptoms, such as fever, headache, and muscle aches, while severe cases can lead to meningitis, encephalitis, and even death.

Diagnosis is typically made through a combination of physical examination, medical history, and laboratory tests, such as blood cultures or PCR (polymerase chain reaction) tests. Treatment typically involves antibiotics, and prompt treatment can significantly reduce the risk of serious complications and death.

Prevention measures include avoiding high-risk foods, such as soft cheeses and hot dogs, and maintaining good hygiene practices, such as washing hands and surfaces regularly. Vaccination against Listeria is not available, but efforts to improve food safety and sanitation can help reduce the risk of listeriosis outbreaks.

Overall, while listeriosis is a serious infection, prompt diagnosis and treatment can significantly improve outcomes for those affected.

* Peripheral T-cell lymphoma (PTCL): This is a rare type of T-cell lymphoma that can develop in the skin, lymph nodes, or other organs.
* Cutaneous T-cell lymphoma (CTCL): This is a type of PTCL that affects the skin and can cause lesions, rashes, and other skin changes.
* Anaplastic large cell lymphoma (ALCL): This is a rare subtype of PTCL that can develop in the lymph nodes, spleen, or bone marrow.
* Adult T-cell leukemia/lymphoma (ATLL): This is a rare and aggressive subtype of PTCL that is caused by the human T-lymphotropic virus type 1 (HTLV-1).

Symptoms of T-cell lymphoma can include:

* Swollen lymph nodes
* Fever
* Fatigue
* Weight loss
* Night sweats
* Skin lesions or rashes

Treatment options for T-cell lymphoma depend on the subtype and stage of the cancer, but may include:

* Chemotherapy
* Radiation therapy
* Immunotherapy
* Targeted therapy

Prognosis for T-cell lymphoma varies depending on the subtype and stage of the cancer, but in general, the prognosis for PTCL is poorer than for other types of non-Hodgkin lymphoma. However, with prompt and appropriate treatment, many people with T-cell lymphoma can achieve long-term remission or even be cured.

The burden of chronic diseases is significant, with over 70% of deaths worldwide attributed to them, according to the World Health Organization (WHO). In addition to the physical and emotional toll they take on individuals and their families, chronic diseases also pose a significant economic burden, accounting for a large proportion of healthcare expenditure.

In this article, we will explore the definition and impact of chronic diseases, as well as strategies for managing and living with them. We will also discuss the importance of early detection and prevention, as well as the role of healthcare providers in addressing the needs of individuals with chronic diseases.

What is a Chronic Disease?

A chronic disease is a condition that lasts for an extended period of time, often affecting daily life and activities. Unlike acute diseases, which have a specific beginning and end, chronic diseases are long-term and persistent. Examples of chronic diseases include:

1. Diabetes
2. Heart disease
3. Arthritis
4. Asthma
5. Cancer
6. Chronic obstructive pulmonary disease (COPD)
7. Chronic kidney disease (CKD)
8. Hypertension
9. Osteoporosis
10. Stroke

Impact of Chronic Diseases

The burden of chronic diseases is significant, with over 70% of deaths worldwide attributed to them, according to the WHO. In addition to the physical and emotional toll they take on individuals and their families, chronic diseases also pose a significant economic burden, accounting for a large proportion of healthcare expenditure.

Chronic diseases can also have a significant impact on an individual's quality of life, limiting their ability to participate in activities they enjoy and affecting their relationships with family and friends. Moreover, the financial burden of chronic diseases can lead to poverty and reduce economic productivity, thus having a broader societal impact.

Addressing Chronic Diseases

Given the significant burden of chronic diseases, it is essential that we address them effectively. This requires a multi-faceted approach that includes:

1. Lifestyle modifications: Encouraging healthy behaviors such as regular physical activity, a balanced diet, and smoking cessation can help prevent and manage chronic diseases.
2. Early detection and diagnosis: Identifying risk factors and detecting diseases early can help prevent or delay their progression.
3. Medication management: Effective medication management is crucial for controlling symptoms and slowing disease progression.
4. Multi-disciplinary care: Collaboration between healthcare providers, patients, and families is essential for managing chronic diseases.
5. Health promotion and disease prevention: Educating individuals about the risks of chronic diseases and promoting healthy behaviors can help prevent their onset.
6. Addressing social determinants of health: Social determinants such as poverty, education, and employment can have a significant impact on health outcomes. Addressing these factors is essential for reducing health disparities and improving overall health.
7. Investing in healthcare infrastructure: Investing in healthcare infrastructure, technology, and research is necessary to improve disease detection, diagnosis, and treatment.
8. Encouraging policy change: Policy changes can help create supportive environments for healthy behaviors and reduce the burden of chronic diseases.
9. Increasing public awareness: Raising public awareness about the risks and consequences of chronic diseases can help individuals make informed decisions about their health.
10. Providing support for caregivers: Chronic diseases can have a significant impact on family members and caregivers, so providing them with support is essential for improving overall health outcomes.

Conclusion

Chronic diseases are a major public health burden that affect millions of people worldwide. Addressing these diseases requires a multi-faceted approach that includes lifestyle changes, addressing social determinants of health, investing in healthcare infrastructure, encouraging policy change, increasing public awareness, and providing support for caregivers. By taking a comprehensive approach to chronic disease prevention and management, we can improve the health and well-being of individuals and communities worldwide.

2. Our research focuses on identifying the genetic mutations that contribute to experimental melanoma and developing targeted therapies.
3. The patient's experimental melanoma had spread to her lungs and liver, so we recommended chemotherapy and immunotherapy treatments.

Viremia is a condition where the virus is present in the bloodstream, outside of infected cells or tissues. This can occur during the acute phase of an infection, when the virus is actively replicating and spreading throughout the body. Viremia can also be seen in chronic infections, where the virus may persist in the blood for longer periods of time.

In some cases, viremia can lead to the development of antibodies against the virus, which can help to neutralize it and prevent its spread. However, if the viremia is not controlled, it can cause serious complications, such as sepsis or organ damage.

Diagnosis of viremia typically involves laboratory tests, such as PCR (polymerase chain reaction) or ELISA (enzyme-linked immunosorbent assay), which can detect the presence of virus in the blood. Treatment of viremia depends on the underlying cause and may include antiviral medications, supportive care, and management of any related complications.

There are several types of melanoma, including:

1. Superficial spreading melanoma: This is the most common type of melanoma, accounting for about 70% of cases. It usually appears as a flat or slightly raised discolored patch on the skin.
2. Nodular melanoma: This type of melanoma is more aggressive and accounts for about 15% of cases. It typically appears as a raised bump on the skin, often with a darker color.
3. Acral lentiginous melanoma: This type of melanoma affects the palms of the hands, soles of the feet, or nail beds and accounts for about 5% of cases.
4. Lentigo maligna melanoma: This type of melanoma usually affects the face and is more common in older adults.

The risk factors for developing melanoma include:

1. Ultraviolet (UV) radiation exposure from the sun or tanning beds
2. Fair skin, light hair, and light eyes
3. A history of sunburns
4. Weakened immune system
5. Family history of melanoma

The symptoms of melanoma can vary depending on the type and location of the cancer. Common symptoms include:

1. Changes in the size, shape, or color of a mole
2. A new mole or growth on the skin
3. A spot or sore that bleeds or crusts over
4. Itching or pain on the skin
5. Redness or swelling around a mole

If melanoma is suspected, a biopsy will be performed to confirm the diagnosis. Treatment options for melanoma depend on the stage and location of the cancer and may include surgery, chemotherapy, radiation therapy, or a combination of these. Early detection and treatment are key to successful outcomes in melanoma cases.

In conclusion, melanoma is a type of skin cancer that can be deadly if not detected early. It is important to practice sun safety, perform regular self-exams, and seek medical attention if any suspicious changes are noticed on the skin. By being aware of the risk factors, symptoms, and treatment options for melanoma, individuals can take steps to protect themselves from this potentially deadly disease.

The most common type of colitis is ulcerative colitis, which affects the rectum and lower part of the colon. The symptoms of ulcerative colitis can include:

* Diarrhea (which may be bloody)
* Abdominal pain and cramping
* Rectal bleeding
* Weight loss
* Fever
* Loss of appetite
* Nausea and vomiting

Microscopic colitis is another type of colitis that is characterized by inflammation in the colon, but without visible ulcers or bleeding. The symptoms of microscopic colitis are similar to those of ulcerative colitis, but may be less severe.

Other types of colitis include:

* Infantile colitis: This is a rare condition that affects babies and young children, and is characterized by diarrhea, fever, and vomiting.
* Isomorphic colitis: This is a rare condition that affects the colon and rectum, and is characterized by inflammation and symptoms similar to ulcerative colitis.
* Radiation colitis: This is a condition that occurs after radiation therapy to the pelvic area, and is characterized by inflammation and symptoms similar to ulcerative colitis.
* Ischemic colitis: This is a condition where there is a reduction in blood flow to the colon, which can lead to inflammation and symptoms such as abdominal pain and diarrhea.

The diagnosis of colitis typically involves a combination of physical examination, medical history, and diagnostic tests such as:

* Colonoscopy: This is a test that uses a flexible tube with a camera on the end to visualize the inside of the colon and rectum.
* Endoscopy: This is a test that uses a flexible tube with a camera on the end to visualize the inside of the esophagus, stomach, and duodenum.
* Stool tests: These are tests that analyze stool samples for signs of inflammation or infection.
* Blood tests: These are tests that analyze blood samples for signs of inflammation or infection.
* Biopsy: This is a test that involves taking a small sample of tissue from the colon and examining it under a microscope for signs of inflammation or infection.

Treatment for colitis depends on the underlying cause, but may include medications such as:

* Aminosalicylates: These are medications that help to reduce inflammation in the colon and relieve symptoms such as diarrhea and abdominal pain. Examples include sulfasalazine (Azulfidine) and mesalamine (Asacol).
* Corticosteroids: These are medications that help to reduce inflammation in the body. They may be used short-term to control acute flares of colitis, or long-term to maintain remission. Examples include prednisone and hydrocortisone.
* Immunomodulators: These are medications that help to suppress the immune system and reduce inflammation. Examples include azathioprine (Imuran) and mercaptopurine (Purinethol).
* Biologics: These are medications that target specific proteins involved in the inflammatory response. Examples include infliximab (Remicade) and adalimumab (Humira).

In addition to medication, lifestyle changes such as dietary modifications and stress management techniques may also be helpful in managing colitis symptoms. Surgery may be necessary in some cases where the colitis is severe or persistent, and involves removing damaged portions of the colon and rectum.

It's important to note that colitis can increase the risk of developing colon cancer, so regular screening for colon cancer is recommended for people with chronic colitis. Additionally, people with colitis may be more susceptible to other health problems such as osteoporosis, osteopenia, and liver disease, so it's important to work closely with a healthcare provider to monitor for these conditions and take steps to prevent them.

The diagnosis of GVHD is based on a combination of clinical findings, laboratory tests, and biopsies. Treatment options include immunosuppressive drugs, corticosteroids, and in severe cases, stem cell transplantation reversal or donor lymphocyte infusion.

Prevention of GVHD includes selecting the right donor, using conditioning regimens that minimize damage to the recipient's bone marrow, and providing appropriate immunosuppression after transplantation. Early detection and management of GVHD are critical to prevent long-term complications and improve survival rates.

The disease is typically induced in laboratory animals such as mice or rats by immunizing them with myelin proteins, such as myelin basic protein (MBP) or proteolipid protein (PLP), emulsified in adjuvants. The resulting immune response leads to the production of autoantibodies and activated T cells that cross the blood-brain barrier and attack the CNS.

EAE is used as a model for MS because it shares many similarities with the human disease, including:

1. Demyelination: EAE induces demyelination of nerve fibers in the CNS, which is also a hallmark of MS.
2. Autoimmune response: The immune response in EAE is triggered by autoantigens, similar to MS.
3. Chronic course: EAE is a chronic disease with recurrent relapses, similar to MS.
4. Lesion distribution: EAE lesions are distributed throughout the CNS, including the cerebral cortex, cerebellum, brainstem, and spinal cord, which is also true for MS.

EAE has been used extensively in the study of MS to investigate the immunopathogenesis of the disease, to develop new diagnostic markers and treatments, and to test the efficacy of potential therapeutic agents.

HIV seropositivity is typically diagnosed through a blood test called an enzyme-linked immunosorbent assay (ELISA). This test detects the presence of antibodies against HIV in the blood by using specific proteins on the surface of the virus. If the test is positive, it means that the individual has been infected with HIV.

HIV seropositivity is an important diagnostic criterion for AIDS (Acquired Immune Deficiency Syndrome), which is a condition that develops when the immune system is severely damaged by HIV infection. AIDS is diagnosed based on a combination of symptoms and laboratory tests, including HIV seropositivity.

HIV seropositivity can be either primary (acute) or chronic. Primary HIV seropositivity occurs when an individual is first infected with HIV and their immune system produces antibodies against the virus. Chronic HIV seropositivity occurs when an individual has been living with HIV for a long time and their immune system has produced antibodies that remain in their bloodstream.

HIV seropositivity can have significant implications for an individual's health and quality of life, as well as their social and economic well-being. It is important for individuals who are HIV seropositive to receive appropriate medical care and support to manage their condition and prevent the transmission of HIV to others.

There are several symptoms of RA, including:

1. Joint pain and stiffness, especially in the hands and feet
2. Swollen and warm joints
3. Redness and tenderness in the affected areas
4. Fatigue, fever, and loss of appetite
5. Loss of range of motion in the affected joints
6. Firm bumps of tissue under the skin (rheumatoid nodules)

RA can be diagnosed through a combination of physical examination, medical history, blood tests, and imaging studies such as X-rays or ultrasound. Treatment typically involves a combination of medications, including nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), and biologic agents. Lifestyle modifications such as exercise and physical therapy can also be helpful in managing symptoms and improving quality of life.

There is no cure for RA, but early diagnosis and aggressive treatment can help to slow the progression of the disease and reduce symptoms. With proper management, many people with RA are able to lead active and fulfilling lives.

The primary symptoms of celiac disease include diarrhea, abdominal pain, fatigue, weight loss, and bloating. However, some people may not experience any symptoms at all, but can still develop complications if the disease is left untreated. These complications can include malnutrition, anemia, osteoporosis, and increased risk of other autoimmune disorders.

The exact cause of celiac disease is unknown, but it is believed to be triggered by a combination of genetic and environmental factors. The disease is more common in people with a family history of celiac disease or other autoimmune disorders. Diagnosis is typically made through a combination of blood tests and intestinal biopsy, and treatment involves a strict gluten-free diet.

Dietary management of celiac disease involves avoiding all sources of gluten, including wheat, barley, rye, and some processed foods that may contain hidden sources of these grains. In some cases, nutritional supplements may be necessary to ensure adequate intake of certain vitamins and minerals.

While there is no known cure for celiac disease, adherence to a strict gluten-free diet can effectively manage the condition and prevent long-term complications. With proper management, people with celiac disease can lead normal, healthy lives.

There are several subtypes of B-cell leukemia, including:

1. Chronic lymphocytic leukemia (CLL): This is the most common type of B-cell leukemia, and it typically affects older adults. CLL is a slow-growing cancer that can progress over time.
2. Acute lymphoblastic leukemia (ALL): This is a fast-growing and aggressive form of B-cell leukemia that can affect people of all ages. ALL is often treated with chemotherapy and sometimes with bone marrow transplantation.
3. Burkitt lymphoma: This is an aggressive form of B-cell leukemia that typically affects older adults in Africa and Asia. Burkitt lymphoma can be treated with chemotherapy and sometimes with bone marrow transplantation.
4. Hairy cell leukemia: This is a rare type of B-cell leukemia that is characterized by the presence of hair-like projections on the surface of cancer cells. Hairy cell leukemia can be treated with chemotherapy and sometimes with bone marrow transplantation.

The diagnosis of B-cell leukemia is based on a combination of physical examination, medical history, laboratory tests, and biopsies. Treatment options for B-cell leukemia include chemotherapy, bone marrow transplantation, and in some cases, targeted therapy with drugs that specifically target cancer cells. The prognosis for B-cell leukemia varies depending on the subtype of the disease and the patient's overall health.

The term "systemic" refers to the fact that the disease affects multiple organ systems, including the skin, joints, kidneys, lungs, and nervous system. LES is a complex condition, and its symptoms can vary widely depending on which organs are affected. Common symptoms include fatigue, fever, joint pain, rashes, and swelling in the extremities.

There are several subtypes of LES, including:

1. Systemic lupus erythematosus (SLE): This is the most common form of the disease, and it can affect anyone, regardless of age or gender.
2. Discoid lupus erythematosus (DLE): This subtype typically affects the skin, causing a red, scaly rash that does not go away.
3. Drug-induced lupus erythematosus: This form of the disease is caused by certain medications, and it usually resolves once the medication is stopped.
4. Neonatal lupus erythematosus: This rare condition affects newborn babies of mothers with SLE, and it can cause liver and heart problems.

There is no cure for LES, but treatment options are available to manage the symptoms and prevent flares. Treatment may include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, immunosuppressive medications, and antimalarial drugs. In severe cases, hospitalization may be necessary to monitor and treat the disease.

It is important for people with LES to work closely with their healthcare providers to manage their condition and prevent complications. With proper treatment and self-care, many people with LES can lead active and fulfilling lives.

CMV infections are more common in people with weakened immune systems, such as those with HIV/AIDS, cancer, or taking immunosuppressive drugs after an organ transplant. In these individuals, CMV can cause severe and life-threatening complications, such as pneumonia, retinitis (inflammation of the retina), and gastrointestinal disease.

In healthy individuals, CMV infections are usually mild and may not cause any symptoms at all. However, in some cases, CMV can cause a mononucleosis-like illness with fever, fatigue, and swollen lymph nodes.

CMV infections are diagnosed through a combination of physical examination, blood tests, and imaging studies such as CT scans or MRI. Treatment is generally not necessary for mild cases, but may include antiviral medications for more severe infections. Prevention strategies include avoiding close contact with individuals who have CMV, practicing good hygiene, and considering immunoprophylaxis (prevention of infection through the use of immune globulin) for high-risk individuals.

Overall, while CMV infections can be serious and life-threatening, they are relatively rare in healthy individuals and can often be treated effectively with supportive care and antiviral medications.

Examples of Immunologic Deficiency Syndromes include:

1. Primary Immunodeficiency Diseases (PIDDs): These are a group of genetic disorders that affect the immune system's ability to function properly. Examples include X-linked agammaglobulinemia, common variable immunodeficiency, and severe combined immunodeficiency.
2. Acquired Immunodeficiency Syndrome (AIDS): This is a condition that results from the human immunodeficiency virus (HIV) infection, which destroys CD4 cells, a type of immune cell that fights off infections.
3. Immune Thrombocytopenic Purpura (ITP): This is an autoimmune disorder that causes the immune system to attack and destroy platelets, which are blood cells that help the blood to clot.
4. Autoimmune Disorders: These are conditions in which the immune system mistakenly attacks and damages healthy cells and tissues in the body. Examples include rheumatoid arthritis, lupus, and multiple sclerosis.
5. Immunosuppressive Therapy-induced Immunodeficiency: This is a condition that occurs as a side effect of medications used to prevent rejection in organ transplant patients. These medications can suppress the immune system, increasing the risk of infections.

Symptoms of Immunologic Deficiency Syndromes can vary depending on the specific disorder and the severity of the immune system dysfunction. Common symptoms include recurrent infections, fatigue, fever, and swollen lymph nodes. Treatment options for these syndromes range from medications to suppress the immune system to surgery or bone marrow transplantation.

In summary, Immunologic Deficiency Syndromes are a group of disorders that result from dysfunction of the immune system, leading to recurrent infections and other symptoms. There are many different types of these syndromes, each with its own set of symptoms and treatment options.

Neoplasm refers to an abnormal growth of cells that can be benign (non-cancerous) or malignant (cancerous). Neoplasms can occur in any part of the body and can affect various organs and tissues. The term "neoplasm" is often used interchangeably with "tumor," but while all tumors are neoplasms, not all neoplasms are tumors.

Types of Neoplasms

There are many different types of neoplasms, including:

1. Carcinomas: These are malignant tumors that arise in the epithelial cells lining organs and glands. Examples include breast cancer, lung cancer, and colon cancer.
2. Sarcomas: These are malignant tumors that arise in connective tissue, such as bone, cartilage, and fat. Examples include osteosarcoma (bone cancer) and soft tissue sarcoma.
3. Lymphomas: These are cancers of the immune system, specifically affecting the lymph nodes and other lymphoid tissues. Examples include Hodgkin lymphoma and non-Hodgkin lymphoma.
4. Leukemias: These are cancers of the blood and bone marrow that affect the white blood cells. Examples include acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).
5. Melanomas: These are malignant tumors that arise in the pigment-producing cells called melanocytes. Examples include skin melanoma and eye melanoma.

Causes and Risk Factors of Neoplasms

The exact causes of neoplasms are not fully understood, but there are several known risk factors that can increase the likelihood of developing a neoplasm. These include:

1. Genetic predisposition: Some people may be born with genetic mutations that increase their risk of developing certain types of neoplasms.
2. Environmental factors: Exposure to certain environmental toxins, such as radiation and certain chemicals, can increase the risk of developing a neoplasm.
3. Infection: Some neoplasms are caused by viruses or bacteria. For example, human papillomavirus (HPV) is a common cause of cervical cancer.
4. Lifestyle factors: Factors such as smoking, excessive alcohol consumption, and a poor diet can increase the risk of developing certain types of neoplasms.
5. Family history: A person's risk of developing a neoplasm may be higher if they have a family history of the condition.

Signs and Symptoms of Neoplasms

The signs and symptoms of neoplasms can vary depending on the type of cancer and where it is located in the body. Some common signs and symptoms include:

1. Unusual lumps or swelling
2. Pain
3. Fatigue
4. Weight loss
5. Change in bowel or bladder habits
6. Unexplained bleeding
7. Coughing up blood
8. Hoarseness or a persistent cough
9. Changes in appetite or digestion
10. Skin changes, such as a new mole or a change in the size or color of an existing mole.

Diagnosis and Treatment of Neoplasms

The diagnosis of a neoplasm usually involves a combination of physical examination, imaging tests (such as X-rays, CT scans, or MRI scans), and biopsy. A biopsy involves removing a small sample of tissue from the suspected tumor and examining it under a microscope for cancer cells.

The treatment of neoplasms depends on the type, size, location, and stage of the cancer, as well as the patient's overall health. Some common treatments include:

1. Surgery: Removing the tumor and surrounding tissue can be an effective way to treat many types of cancer.
2. Chemotherapy: Using drugs to kill cancer cells can be effective for some types of cancer, especially if the cancer has spread to other parts of the body.
3. Radiation therapy: Using high-energy radiation to kill cancer cells can be effective for some types of cancer, especially if the cancer is located in a specific area of the body.
4. Immunotherapy: Boosting the body's immune system to fight cancer can be an effective treatment for some types of cancer.
5. Targeted therapy: Using drugs or other substances to target specific molecules on cancer cells can be an effective treatment for some types of cancer.

Prevention of Neoplasms

While it is not always possible to prevent neoplasms, there are several steps that can reduce the risk of developing cancer. These include:

1. Avoiding exposure to known carcinogens (such as tobacco smoke and radiation)
2. Maintaining a healthy diet and lifestyle
3. Getting regular exercise
4. Not smoking or using tobacco products
5. Limiting alcohol consumption
6. Getting vaccinated against certain viruses that are associated with cancer (such as human papillomavirus, or HPV)
7. Participating in screening programs for early detection of cancer (such as mammograms for breast cancer and colonoscopies for colon cancer)
8. Avoiding excessive exposure to sunlight and using protective measures such as sunscreen and hats to prevent skin cancer.

It's important to note that not all cancers can be prevented, and some may be caused by factors that are not yet understood or cannot be controlled. However, by taking these steps, individuals can reduce their risk of developing cancer and improve their overall health and well-being.

Symptoms of type 1 diabetes can include increased thirst and urination, blurred vision, fatigue, weight loss, and skin infections. If left untreated, type 1 diabetes can lead to serious complications such as kidney damage, nerve damage, and blindness.

Type 1 diabetes is diagnosed through a combination of physical examination, medical history, and laboratory tests such as blood glucose measurements and autoantibody tests. Treatment typically involves insulin therapy, which can be administered via injections or an insulin pump, as well as regular monitoring of blood glucose levels and appropriate lifestyle modifications such as a healthy diet and regular exercise.

There are several types of disease susceptibility, including:

1. Genetic predisposition: This refers to the inherent tendency of an individual to develop a particular disease due to their genetic makeup. For example, some families may have a higher risk of developing certain diseases such as cancer or heart disease due to inherited genetic mutations.
2. Environmental susceptibility: This refers to the increased risk of developing a disease due to exposure to environmental factors such as pollutants, toxins, or infectious agents. For example, someone who lives in an area with high levels of air pollution may be more susceptible to developing respiratory problems.
3. Lifestyle susceptibility: This refers to the increased risk of developing a disease due to unhealthy lifestyle choices such as smoking, lack of exercise, or poor diet. For example, someone who smokes and is overweight may be more susceptible to developing heart disease or lung cancer.
4. Immune system susceptibility: This refers to the increased risk of developing a disease due to an impaired immune system. For example, people with autoimmune disorders such as HIV/AIDS or rheumatoid arthritis may be more susceptible to opportunistic infections.

Understanding disease susceptibility can help healthcare providers identify individuals who are at risk of developing certain diseases and provide preventive measures or early intervention to reduce the risk of disease progression. Additionally, genetic testing can help identify individuals with a high risk of developing certain diseases, allowing for earlier diagnosis and treatment.

In summary, disease susceptibility refers to the predisposition of an individual to develop a particular disease or condition due to various factors such as genetics, environment, lifestyle choices, and immune system function. Understanding disease susceptibility can help healthcare providers identify individuals at risk and provide appropriate preventive measures or early intervention to reduce the risk of disease progression.

Crohn's disease can affect any part of the GI tract, from the mouth to the anus, and causes symptoms such as abdominal pain, diarrhea, fatigue, and weight loss. Ulcerative colitis primarily affects the colon and rectum and causes symptoms such as bloody stools, abdominal pain, and weight loss.

Both Crohn's disease and ulcerative colitis are chronic conditions, meaning they cannot be cured but can be managed with medication and lifestyle changes. Treatment options for IBD include anti-inflammatory medications, immunosuppressants, and biologics. In severe cases, surgery may be necessary to remove damaged portions of the GI tract.

There is no known cause of IBD, although genetics, environmental factors, and an abnormal immune response are thought to play a role. The condition can have a significant impact on quality of life, particularly if left untreated or poorly managed. Complications of IBD include malnutrition, osteoporosis, and increased risk of colon cancer.

Preventing and managing IBD requires a comprehensive approach that includes medication, dietary changes, stress management, and regular follow-up with a healthcare provider. With proper treatment and lifestyle modifications, many people with IBD are able to manage their symptoms and lead active, fulfilling lives.

There are several types of lymphoma, including:

1. Hodgkin lymphoma: This is a type of lymphoma that originates in the white blood cells called Reed-Sternberg cells. It is characterized by the presence of giant cells with multiple nucleoli.
2. Non-Hodgkin lymphoma (NHL): This is a type of lymphoma that does not meet the criteria for Hodgkin lymphoma. There are many subtypes of NHL, each with its own unique characteristics and behaviors.
3. Cutaneous lymphoma: This type of lymphoma affects the skin and can take several forms, including cutaneous B-cell lymphoma and cutaneous T-cell lymphoma.
4. Primary central nervous system (CNS) lymphoma: This is a rare type of lymphoma that develops in the brain or spinal cord.
5. Post-transplantation lymphoproliferative disorder (PTLD): This is a type of lymphoma that develops in people who have undergone an organ transplant, often as a result of immunosuppressive therapy.

The symptoms of lymphoma can vary depending on the type and location of the cancer. Some common symptoms include:

* Swollen lymph nodes
* Fever
* Fatigue
* Weight loss
* Night sweats
* Itching

Lymphoma is diagnosed through a combination of physical examination, imaging tests (such as CT scans or PET scans), and biopsies. Treatment options for lymphoma depend on the type and stage of the cancer, and may include chemotherapy, radiation therapy, immunotherapy, or stem cell transplantation.

Overall, lymphoma is a complex and diverse group of cancers that can affect people of all ages and backgrounds. While it can be challenging to diagnose and treat, advances in medical technology and research have improved the outlook for many patients with lymphoma.

Also known as Burkitt's Lymphoma.

The symptoms of Arenaviridae infections can vary depending on the specific virus causing the infection, but they may include:

* Fever
* Headache
* Muscle pain
* Joint pain
* Sore throat
* Swollen lymph nodes
* Rash
* Seizures
* Meningitis
* Encephalitis (inflammation of the brain)

Some Arenaviridae infections can be transmitted to humans through contact with infected rodents or other animals, while others are spread by blood transfusions or organ transplantation. There is no specific treatment for Arenaviridae infections, and treatment is primarily focused on relieving symptoms and managing complications.

Examples of Arenaviridae infections include:

* Lymphocytic choriomeningitis (LCMV)
* Venezuelan equine encephalitis (VEE)
* Eastern equine encephalitis (EEE)
* Western equine encephalitis (WEE)
* Sabia virus infection

It's important to note that Arenaviridae infections can be severe and potentially life-threatening, so if you suspect you or someone else may have been infected, it's important to seek medical attention immediately.

Multiple myeloma is the second most common type of hematologic cancer after non-Hodgkin's lymphoma, accounting for approximately 1% of all cancer deaths worldwide. It is more common in older adults, with most patients being diagnosed over the age of 65.

The exact cause of multiple myeloma is not known, but it is believed to be linked to genetic mutations that occur in the plasma cells. There are several risk factors that have been associated with an increased risk of developing multiple myeloma, including:

1. Family history: Having a family history of multiple myeloma or other plasma cell disorders increases the risk of developing the disease.
2. Age: The risk of developing multiple myeloma increases with age, with most patients being diagnosed over the age of 65.
3. Race: African Americans are at higher risk of developing multiple myeloma than other races.
4. Obesity: Being overweight or obese may increase the risk of developing multiple myeloma.
5. Exposure to certain chemicals: Exposure to certain chemicals such as pesticides, solvents, and heavy metals has been linked to an increased risk of developing multiple myeloma.

The symptoms of multiple myeloma can vary depending on the severity of the disease and the organs affected. Common symptoms include:

1. Bone pain: Pain in the bones, particularly in the spine, ribs, or long bones, is a common symptom of multiple myeloma.
2. Fatigue: Feeling tired or weak is another common symptom of the disease.
3. Infections: Patients with multiple myeloma may be more susceptible to infections due to the impaired functioning of their immune system.
4. Bone fractures: Weakened bones can lead to an increased risk of fractures, particularly in the spine, hips, or ribs.
5. Kidney problems: Multiple myeloma can cause damage to the kidneys, leading to problems such as kidney failure or proteinuria (excess protein in the urine).
6. Anemia: A low red blood cell count can cause anemia, which can lead to fatigue, weakness, and shortness of breath.
7. Increased calcium levels: High levels of calcium in the blood can cause symptoms such as nausea, vomiting, constipation, and confusion.
8. Neurological problems: Multiple myeloma can cause neurological problems such as headaches, numbness or tingling in the arms and legs, and difficulty with coordination and balance.

The diagnosis of multiple myeloma typically involves a combination of physical examination, medical history, and laboratory tests. These may include:

1. Complete blood count (CBC): A CBC can help identify abnormalities in the numbers and characteristics of different types of blood cells, including red blood cells, white blood cells, and platelets.
2. Serum protein electrophoresis (SPEP): This test measures the levels of different proteins in the blood, including immunoglobulins (antibodies) and abnormal proteins produced by myeloma cells.
3. Urine protein electrophoresis (UPEP): This test measures the levels of different proteins in the urine.
4. Immunofixation: This test is used to identify the type of antibody produced by myeloma cells and to rule out other conditions that may cause similar symptoms.
5. Bone marrow biopsy: A bone marrow biopsy involves removing a sample of tissue from the bone marrow for examination under a microscope. This can help confirm the diagnosis of multiple myeloma and determine the extent of the disease.
6. Imaging tests: Imaging tests such as X-rays, CT scans, or MRI scans may be used to assess the extent of bone damage or other complications of multiple myeloma.
7. Genetic testing: Genetic testing may be used to identify specific genetic abnormalities that are associated with multiple myeloma and to monitor the response of the disease to treatment.

It's important to note that not all patients with MGUS or smoldering myeloma will develop multiple myeloma, and some patients with multiple myeloma may not have any symptoms at all. However, if you are experiencing any of the symptoms listed above or have a family history of multiple myeloma, it's important to talk to your doctor about your risk and any tests that may be appropriate for you.

There are several types of skin neoplasms, including:

1. Basal cell carcinoma (BCC): This is the most common type of skin cancer, and it usually appears as a small, fleshy bump or a flat, scaly patch. BCC is highly treatable, but if left untreated, it can grow and invade surrounding tissue.
2. Squamous cell carcinoma (SCC): This type of skin cancer is less common than BCC but more aggressive. It typically appears as a firm, flat, or raised bump on sun-exposed areas. SCC can spread to other parts of the body if left untreated.
3. Melanoma: This is the most serious type of skin cancer, accounting for only 1% of all skin neoplasms but responsible for the majority of skin cancer deaths. Melanoma can appear as a new or changing mole, and it's essential to recognize the ABCDE signs (Asymmetry, Border irregularity, Color variation, Diameter >6mm, Evolving size, shape, or color) to detect it early.
4. Sebaceous gland carcinoma: This rare type of skin cancer originates in the oil-producing glands of the skin and can appear as a firm, painless nodule on the forehead, nose, or other oily areas.
5. Merkel cell carcinoma: This is a rare and aggressive skin cancer that typically appears as a firm, shiny bump on the skin. It's more common in older adults and those with a history of sun exposure.
6. Cutaneous lymphoma: This type of cancer affects the immune system and can appear as a rash, nodules, or tumors on the skin.
7. Kaposi sarcoma: This is a rare type of skin cancer that affects people with weakened immune systems, such as those with HIV/AIDS. It typically appears as a flat, red or purple lesion on the skin.

While skin cancers are generally curable when detected early, it's important to be aware of your skin and notice any changes or unusual spots, especially if you have a history of sun exposure or other risk factors. If you suspect anything suspicious, see a dermatologist for an evaluation and potential biopsy. Remember, prevention is key to avoiding the harmful effects of UV radiation and reducing your risk of developing skin cancer.

Dermatitis, contact can be acute or chronic, depending on the severity and duration of the exposure. In acute cases, the symptoms may resolve within a few days after removing the offending substance. Chronic dermatitis, on the other hand, can persist for weeks or even months, and may require ongoing treatment to manage the symptoms.

The symptoms of contact dermatitis can vary depending on the individual and the severity of the exposure. Common symptoms include:

* Redness and inflammation of the skin
* Itching and burning sensations
* Swelling and blistering
* Cracks or fissures in the skin
* Difficulty healing or recurring infections

In severe cases, contact dermatitis can lead to complications such as:

* Infection with bacteria or fungi
* Scarring and disfigurement
* Emotional distress and anxiety

Diagnosis of contact dermatitis is typically made based on the patient's medical history and physical examination. Allergic patch testing may also be performed to identify specific allergens that are causing the condition.

Treatment for contact dermatitis usually involves avoiding the offending substance and using topical or oral medications to manage symptoms. In severe cases, systemic corticosteroids or immunosuppressants may be prescribed. Phototherapy and alternative therapies such as herbal remedies or acupuncture may also be considered.

Prevention of contact dermatitis involves identifying and avoiding substances that cause an allergic reaction or skin irritation. Individuals with a history of contact dermatitis should take precautions when handling new substances, and should be aware of the potential for cross-reactivity between different allergens.

Orthomyxoviridae infections are a group of viral infections caused by the Orthomyxoviridae family of viruses, which includes influenza A and B viruses, as well as other related viruses. These infections can affect both humans and animals and can cause a range of symptoms, from mild to severe.

The most common type of Orthomyxoviridae infection is seasonal influenza, which occurs when the virus is transmitted from person to person through the air or by contact with infected surfaces. Other types of Orthomyxoviridae infections include:

1. Pandemic influenza: This occurs when a new strain of the virus emerges and spreads quickly around the world, causing widespread illness and death. Examples of pandemic influenza include the Spanish flu of 1918 and the Asian flu of 1957.
2. Avian influenza: This occurs when birds are infected with the virus and can be transmitted to humans through close contact with infected birds or their droppings.
3. Swine influenza: This occurs when pigs are infected with the virus and can be transmitted to humans through close contact with infected pigs or their droppings.
4. H5N1 and H7N9: These are two specific types of bird flu viruses that have caused serious outbreaks in humans in recent years.

Symptoms of Orthomyxoviridae infections can include fever, cough, sore throat, runny nose, muscle aches, and fatigue. In severe cases, these infections can lead to pneumonia, bronchitis, and other respiratory complications, as well as hospitalization and even death.

Diagnosis of Orthomyxoviridae infections is typically made through a combination of physical examination, medical history, and laboratory tests, such as PCR (polymerase chain reaction) or viral culture. Treatment is generally focused on relieving symptoms and supporting the immune system, with antiviral medications may be used in severe cases.

Prevention of Orthomyxoviridae infections can include avoiding close contact with infected birds or pigs, wearing protective clothing and gear when handling animals, and practicing good hygiene such as washing hands frequently. Vaccines are also available for some species of birds and pigs to protect against these viruses.

Overall, Orthomyxoviridae is a family of viruses that can cause serious illness in humans and other animals, and it's important to take precautions to prevent exposure and spread of these viruses.

UC can be challenging to diagnose and treat, and there is no known cure. However, with proper management, it is possible for people with UC to experience long periods of remission and improve their quality of life. Treatment options include medications such as aminosalicylates, corticosteroids, and immunomodulators, as well as surgery in severe cases.

It's important for individuals with UC to work closely with their healthcare provider to develop a personalized treatment plan that takes into account their specific symptoms and needs. With the right treatment and support, many people with UC are able to manage their symptoms and lead active, fulfilling lives.

Herpesviridae infections are caused by the Herpesviridae family of viruses and can be transmitted through skin-to-skin contact, sexual contact, or from mother to child during pregnancy or childbirth. Symptoms of herpesviridae infections can vary depending on the type of virus and the individual infected, but may include fever, fatigue, muscle aches, and skin sores or rashes.

There is no cure for herpesviridae infections, but antiviral medications can help manage symptoms and reduce the risk of transmission to others. Good hygiene practices, such as washing hands regularly and avoiding close contact with those who are infected, can also help prevent the spread of these viruses.

Some common types of herpesviridae infections include:

* Herpes simplex virus (HSV) - Causes cold sores and genital herpes.
* Varicella-zoster virus (VZV) - Causes chickenpox and shingles.
* Human herpesvirus 8 (HHV-8) - Associated with certain types of cancer, such as Kaposi's sarcoma.

Vaccinia is most commonly associated with smallpox, which is caused by a similar virus and was eradicated in the late 1970s through widespread vaccination. However, there have been occasional outbreaks of vaccinia in the United States and other countries since then, often linked to laboratory accidents or deliberate releases of the virus.

The treatment of vaccinia typically involves supportive care, such as rest, hydration, and antipyretic medications to reduce fever. Antiviral medications may also be used in some cases. Prevention of the disease relies on avoiding contact with infected animals or people, and on following proper infection control practices in laboratory and healthcare settings.

Vaccinia is a serious viral infection that can have severe consequences if left untreated. It is important to seek medical attention immediately if symptoms persist or worsen over time.

Symptoms of EBV infection can vary widely, ranging from asymptomatic to severe, and may include:

* Fatigue
* Fever
* Sore throat
* Swollen lymph nodes in the neck and armpits
* Swollen liver or spleen
* Rash
* Headaches
* Muscle weakness

In some cases, EBV can lead to more serious complications such as infectious mononucleosis (IM), also known as glandular fever, which can cause:

* Enlarged liver and spleen
* Splenomegaly (enlargement of the spleen)
* Hepatomegaly (enlargement of the liver)
* Thrombocytopenia (low platelet count)
* Anemia (low red blood cell count)
* Leukopenia (low white blood cell count)

EBV is also associated with an increased risk of developing certain types of cancer, including Burkitt lymphoma, Hodgkin lymphoma, and nasopharyngeal carcinoma.

There is no specific treatment for EBV infections, and most cases resolve on their own within a few weeks. Antiviral medications may be prescribed in severe cases or to prevent complications. Rest, hydration, and over-the-counter pain relief medication can help alleviate symptoms.

There are several possible causes of lymphocytosis, including:

1. Infection: Lymphocytosis can be caused by a variety of infections, such as viral or bacterial infections.
2. Autoimmune disorders: Conditions such as rheumatoid arthritis, lupus, and multiple sclerosis can cause an abnormal increase in lymphocytes.
3. Cancer: Lymphocytosis can be a symptom of certain types of cancer, such as Hodgkin's disease and non-Hodgkin's lymphoma.
4. Reaction to medication: Certain medications, such as antibiotics and chemotherapy drugs, can cause lymphocytosis.
5. Genetic disorders: Certain genetic disorders, such as X-linked agammaglobulinemia, can cause lymphocytosis.

Symptoms of lymphocytosis may include swollen lymph nodes, fatigue, fever, and weight loss. Treatment depends on the underlying cause of the condition, and may involve antibiotics, chemotherapy, or other medications. In some cases, no treatment is necessary, as the condition may resolve on its own over time.

Examples of delayed hypersensitivity reactions include contact dermatitis (a skin reaction to an allergic substance), tuberculin reactivity (a reaction to the bacteria that cause tuberculosis), and sarcoidosis (a condition characterized by inflammation in various organs, including the lungs and lymph nodes).

Delayed hypersensitivity reactions are important in the diagnosis and management of allergic disorders and other immune-related conditions. They can be detected through a variety of tests, including skin prick testing, patch testing, and blood tests. Treatment for delayed hypersensitivity reactions depends on the underlying cause and may involve medications such as antihistamines, corticosteroids, or immunosuppressants.

The symptoms of MS can vary widely depending on the location and severity of the damage to the CNS. Common symptoms include:

* Weakness, numbness, or tingling in the limbs
* Fatigue
* Vision problems, such as blurred vision, double vision, or loss of vision
* Difficulty with balance and coordination
* Tremors or spasticity
* Memory and concentration problems
* Mood changes, such as depression or mood swings
* Bladder and bowel problems

There is no cure for MS, but various treatments can help manage the symptoms and slow the progression of the disease. These treatments include:

* Disease-modifying therapies (DMTs) - These medications are designed to reduce the frequency and severity of relapses, and they can also slow the progression of disability. Examples of DMTs include interferons, glatiramer acetate, natalizumab, fingolimod, dimethyl fumarate, teriflunomide, and alemtuzumab.
* Steroids - Corticosteroids can help reduce inflammation during relapses, but they are not a long-term solution.
* Pain management medications - Pain relievers, such as acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs), can help manage pain caused by MS.
* Muscle relaxants - These medications can help reduce spasticity and tremors.
* Physical therapy - Physical therapy can help improve mobility, balance, and strength.
* Occupational therapy - Occupational therapy can help with daily activities and assistive devices.
* Speech therapy - Speech therapy can help improve communication and swallowing difficulties.
* Psychological counseling - Counseling can help manage the emotional and psychological aspects of MS.

It's important to note that each person with MS is unique, and the best treatment plan will depend on the individual's specific symptoms, needs, and preferences. It's essential to work closely with a healthcare provider to find the most effective treatment plan.

There are several subtypes of NHL, including:

1. B-cell lymphomas (such as diffuse large B-cell lymphoma and follicular lymphoma)
2. T-cell lymphomas (such as peripheral T-cell lymphoma and mycosis fungoides)
3. Natural killer cell lymphomas (such as nasal NK/T-cell lymphoma)
4. Histiocyte-rich B-cell lymphoma
5. Primary mediastinal B-cell lymphoma
6. Mantle cell lymphoma
7. Waldenström macroglobulinemia
8. Lymphoplasmacytoid lymphoma
9. Myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) related lymphoma

These subtypes can be further divided into other categories based on the specific characteristics of the cancer cells.

Symptoms of NHL can vary depending on the location and size of the tumor, but may include:

* Swollen lymph nodes in the neck, underarm, or groin
* Fever
* Fatigue
* Weight loss
* Night sweats
* Itching
* Abdominal pain
* Swollen spleen

Treatment for NHL typically involves a combination of chemotherapy, radiation therapy, and in some cases, targeted therapy or immunotherapy. The specific treatment plan will depend on the subtype of NHL, the stage of the cancer, and other individual factors.

Overall, NHL is a complex and diverse group of cancers that require specialized care from a team of medical professionals, including hematologists, oncologists, radiation therapists, and other support staff. With advances in technology and treatment options, many people with NHL can achieve long-term remission or a cure.

Types of experimental neoplasms include:

* Xenografts: tumors that are transplanted into animals from another species, often humans.
* Transgenic tumors: tumors that are created by introducing cancer-causing genes into an animal's genome.
* Chemically-induced tumors: tumors that are caused by exposure to certain chemicals or drugs.

The use of experimental neoplasms in research has led to significant advances in our understanding of cancer biology and the development of new treatments for the disease. However, the use of animals in cancer research is a controversial topic and alternatives to animal models are being developed and implemented.

The symptoms of lymphoma, T-cell, cutaneous can vary depending on the location and severity of the cancer, but may include:

* Red, scaly patches or lesions on the skin
* Itching, burning, or pain on the skin
* Swollen lymph nodes
* Fever
* Fatigue

Lymphoma, T-cell, cutaneous is a relatively rare type of cancer, and it can be difficult to diagnose. A doctor will typically perform a biopsy (removing a small sample of tissue from the affected area) to confirm the diagnosis. Treatment options may include:

* Topical medications (applied directly to the skin)
* Phototherapy (exposure to specific wavelengths of light)
* Chemotherapy (using drugs to kill cancer cells)
* Radiation therapy (using high-energy radiation to kill cancer cells)
* Targeted therapy (using drugs or other substances to target specific molecules on cancer cells)

Overall, the prognosis for lymphoma, T-cell, cutaneous is generally good, especially if the cancer is caught early and treated effectively. However, it can be a challenging condition to treat, and patients may experience significant discomfort and disfigurement.

DLBCL is characterized by the rapid growth of malignant B cells in the lymph nodes, spleen, bone marrow, and other organs. These cells can also spread to other parts of the body through the bloodstream or lymphatic system. The disease is often aggressive and can progress quickly without treatment.

The symptoms of DLBCL vary depending on the location and extent of the disease, but they may include:

* Swollen lymph nodes in the neck, underarm, or groin
* Fever
* Fatigue
* Night sweats
* Weight loss
* Abdominal pain or discomfort
* Itching

The diagnosis of DLBCL is based on a combination of physical examination findings, imaging studies (such as CT scans or PET scans), and biopsy results. Treatment typically involves a combination of chemotherapy, radiation therapy, and in some cases, immunotherapy or targeted therapy. The prognosis for DLBCL has improved significantly over the past few decades, with overall survival rates ranging from 60% to 80%, depending on the stage and other factors.

The symptoms of T-cell leukemia can vary depending on the severity of the disease, but they may include:

* Fatigue
* Weakness
* Frequent infections
* Easy bruising or bleeding
* Swollen lymph nodes
* Pain in the bones or joints
* Headaches
* Confusion or seizures (in severe cases)

T-cell leukemia is diagnosed through a combination of physical examination, blood tests, and bone marrow biopsy. Treatment typically involves chemotherapy and/or radiation therapy to kill cancer cells and restore the body's normal production of blood cells. In some cases, bone marrow transplantation may be recommended.

The prognosis for T-cell leukemia varies depending on the patient's age and overall health, as well as the aggressiveness of the disease. However, with current treatments, the 5-year survival rate is around 70% for children and adolescents, and around 40% for adults.

It's important to note that T-cell leukemia is relatively rare compared to other types of leukemia, such as acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL). However, it can be a very aggressive and difficult-to-treat form of cancer, and patients with T-cell leukemia often require intensive treatment and close follow-up care.

There are two main forms of TB:

1. Active TB: This is the form of the disease where the bacteria are actively growing and causing symptoms such as coughing, fever, chest pain, and fatigue. Active TB can be contagious and can spread to others if not treated properly.
2. Latent TB: This is the form of the disease where the bacteria are present in the body but are not actively growing or causing symptoms. People with latent TB do not feel sick and are not contagious, but they can still become sick with active TB if their immune system is weakened.

TB is a major public health concern, especially in developing countries where access to healthcare may be limited. The disease is diagnosed through a combination of physical examination, medical imaging, and laboratory tests such as skin tests or blood tests. Treatment for TB typically involves a course of antibiotics, which can be effective in curing the disease if taken properly. However, drug-resistant forms of TB have emerged in some parts of the world, making treatment more challenging.

Preventive measures against TB include:

1. Vaccination with BCG (Bacille Calmette-Guérin) vaccine, which can provide some protection against severe forms of the disease but not against latent TB.
2. Avoiding close contact with people who have active TB, especially if they are coughing or sneezing.
3. Practicing good hygiene, such as covering one's mouth when coughing or sneezing and regularly washing hands.
4. Getting regular screenings for TB if you are in a high-risk group, such as healthcare workers or people with weakened immune systems.
5. Avoiding sharing personal items such as towels, utensils, or drinking glasses with people who have active TB.

Overall, while TB is a serious disease that can be challenging to treat and prevent, with the right measures in place, it is possible to reduce its impact on public health and improve outcomes for those affected by the disease.

There are several different types of leukemia, including:

1. Acute Lymphoblastic Leukemia (ALL): This is the most common type of leukemia in children, but it can also occur in adults. It is characterized by an overproduction of immature white blood cells called lymphoblasts.
2. Acute Myeloid Leukemia (AML): This type of leukemia affects the bone marrow's ability to produce red blood cells, platelets, and other white blood cells. It can occur at any age but is most common in adults.
3. Chronic Lymphocytic Leukemia (CLL): This type of leukemia affects older adults and is characterized by the slow growth of abnormal white blood cells called lymphocytes.
4. Chronic Myeloid Leukemia (CML): This type of leukemia is caused by a genetic mutation in a gene called BCR-ABL. It can occur at any age but is most common in adults.
5. Hairy Cell Leukemia: This is a rare type of leukemia that affects older adults and is characterized by the presence of abnormal white blood cells called hairy cells.
6. Myelodysplastic Syndrome (MDS): This is a group of disorders that occur when the bone marrow is unable to produce healthy blood cells. It can lead to leukemia if left untreated.

Treatment for leukemia depends on the type and severity of the disease, but may include chemotherapy, radiation therapy, targeted therapy, or stem cell transplantation.

Hodgkin Disease can spread to other parts of the body through the lymphatic system, and it can affect people of all ages, although it is most common in young adults and teenagers. The symptoms of Hodgkin Disease can vary depending on the stage of the disease, but they may include swollen lymph nodes, fever, night sweats, fatigue, weight loss, and itching.

There are several types of Hodgkin Disease, including:

* Classical Hodgkin Disease: This is the most common type of Hodgkin Disease and is characterized by the presence of Reed-Sternberg cells.
* Nodular Lymphocytic predominant Hodgkin Disease: This type of Hodgkin Disease is characterized by the presence of nodules in the lymph nodes.
* Mixed Cellularity Hodgkin Disease: This type of Hodgkin Disease is characterized by a mixture of Reed-Sternberg cells and other immune cells.

Hodgkin Disease is usually diagnosed with a biopsy, which involves removing a sample of tissue from the affected lymph node or other area and examining it under a microscope for cancer cells. Treatment for Hodgkin Disease typically involves chemotherapy, radiation therapy, or a combination of both. In some cases, bone marrow or stem cell transplantation may be necessary.

The prognosis for Hodgkin Disease is generally good, especially if the disease is detected and treated early. According to the American Cancer Society, the 5-year survival rate for people with Hodgkin Disease is about 85%. However, the disease can sometimes recur after treatment, and the long-term effects of radiation therapy and chemotherapy can include infertility, heart problems, and an increased risk of secondary cancers.

Hodgkin Disease is a rare form of cancer that affects the immune system. It is most commonly diagnosed in young adults and is usually treatable with chemotherapy or radiation therapy. However, the disease can sometimes recur after treatment, and the long-term effects of treatment can include infertility, heart problems, and an increased risk of secondary cancers.

These proteins are essential for white blood cells to stick together and migrate through the blood vessels into tissues, where they can fight off infections. The symptoms of Leukocyte Adhesion Deficiency syndrome vary depending on which gene is mutated and the severity of the mutation.

Some of the common symptoms include recurrent or persistent infections, poor wound healing, delayed development of the skin and mucous membranes, and difficulty fighting off certain types of bacteria, viruses, and fungi. The diagnosis of Leukocyte Adhesion Deficiency syndrome is based on a combination of clinical findings, laboratory tests that measure the function of white blood cells, and genetic analysis that identifies mutations in one of the genes involved in leukocyte adhesion.

Treatment for Leukocyte Adhesion Deficiency syndrome usually involves antibiotics to prevent or treat infections, topical creams or ointments to promote wound healing, and occasionally immunoglobulin replacement therapy to boost the immune system.

Several types of Leukocyte Adhesion Deficiency syndrome exist, each caused by a mutation in a different gene involved in leukocyte adhesion. The most common form of this disorder is called LAMA2 deficiency or Hereditary Angioedema with Giant Lymph Node.

Overall, early diagnosis and appropriate treatment can help manage symptoms and prevent complications associated with Leukocyte Adhesion Deficiency syndrome.

Leukocyte adhesion deficiency (LAD) is a group of rare genetic disorders characterized by impaired leukocyte trafficking and immune dysfunction. The disorders are caused by mutations in genes encoding proteins involved in leukocyte adhesion and migration, such as integrins and chemokine receptors.

There are several types of LAD, each with distinct clinical features and symptoms. The most common form of the disorder is LAMA2 deficiency, which affects approximately 1 in 50,000 individuals worldwide. Other forms of LAD include CD1a and CD1b deficiencies, which are less common but can have overlapping clinical features with LAMA2 deficiency.

The primary symptom of LAD is recurrent skin infections, particularly in childhood. Patients may also experience respiratory infections, gastrointestinal infections, and abscesses. In addition, some patients with LAD may develop chronic inflammation and fibrosis, which can lead to severe complications such as renal failure or blindness.

The diagnosis of LAD is based on a combination of clinical findings, laboratory tests, and genetic analysis. Laboratory tests may include flow cytometry, which can assess leukocyte function and adhesion properties, and molecular genetic testing, which can identify mutations in genes encoding integrins or other adhesion molecules.

Treatment of LAD typically involves antibiotics for recurrent skin and soft tissue infections, as well as management of any underlying chronic inflammation or fibrosis. In some cases, bone marrow transplantation may be considered as a curative therapy.

Overall, LAD is a rare and complex disorder that requires careful diagnosis and management by a multidisciplinary team of healthcare professionals. With appropriate treatment, many patients with LAD can lead active and productive lives, although some may experience ongoing complications or lifelong immune dysfunction.

Examples of AROIs include:

1. Pneumocystis pneumonia (PCP): a type of pneumonia caused by the fungus Pneumocystis jirovecii.
2. Tuberculosis (TB): a bacterial infection that can affect the lungs, brain, or other organs.
3. Toxoplasmosis: an infection caused by the parasite Toxoplasma gondii that can affect the brain, eyes, and other organs.
4. Cryptococcosis: a fungal infection that can affect the lungs, brain, or skin.
5. Histoplasmosis: a fungal infection caused by Histoplasma capsulatum that can affect the lungs, skin, and other organs.
6. Aspergillosis: a fungal infection caused by Aspergillus species that can affect the lungs, sinuses, and other organs.
7. Candidiasis: a fungal infection caused by Candida species that can affect the mouth, throat, vagina, or skin.
8. Kaposi's sarcoma: a type of cancer that is caused by the human herpesvirus 8 (HHV-8) and can affect the skin and lymph nodes.
9. Wasting syndrome: a condition characterized by weight loss, fatigue, and diarrhea.
10. Opportunistic infections that can affect the gastrointestinal tract, such as cryptosporidiosis and isosporiasis.

AROIs are a major cause of morbidity and mortality in individuals with HIV/AIDS, and they can be prevented or treated with antimicrobial therapy, supportive care, and other interventions.

Thymoma can be broadly classified into two main types:

1. Benign thymoma: This type of thymoma is non-cancerous and does not spread to other parts of the body. It is usually small in size and may not cause any symptoms.
2. Malignant thymoma: This type of thymoma is cancerous and can spread to other parts of the body, including the lungs, liver, and bone marrow. Malignant thymomas are more aggressive than benign thymomas and can be life-threatening if not treated promptly.

The exact cause of thymoma is not known, but it is believed to arise from abnormal cell growth in the thymus gland. Some risk factors that may increase the likelihood of developing thymoma include:

1. Genetic mutations: Certain genetic mutations, such as those affecting the TREX1 gene, can increase the risk of developing thymoma.
2. Radiation exposure: Exposure to radiation, such as from radiation therapy, may increase the risk of developing thymoma.
3. Thymic hyperplasia: Enlargement of the thymus gland, known as thymic hyperplasia, may increase the risk of developing thymoma.

The symptoms of thymoma can vary depending on the size and location of the tumor. Some common symptoms include:

1. Chest pain or discomfort
2. Shortness of breath
3. Coughing
4. Fatigue
5. Weight loss
6. Fever
7. Night sweats
8. Pain in the arm or shoulder

Thymoma is diagnosed through a combination of imaging tests, such as computed tomography (CT) scans and magnetic resonance imaging (MRI), and biopsy, which involves removing a sample of tissue from the thymus gland for examination under a microscope. Treatment options for thymoma depend on the stage and aggressiveness of the tumor, and may include:

1. Surgery: Removing the tumor through surgery is often the first line of treatment for thymoma.
2. Radiation therapy: High-energy beams can be used to kill cancer cells and shrink the tumor.
3. Chemotherapy: Drugs can be used to kill cancer cells and shrink the tumor.
4. Targeted therapy: Drugs that target specific molecules involved in the growth and spread of cancer cells can be used to treat thymoma.
5. Immunotherapy: Treatments that use the body's immune system to fight cancer, such as checkpoint inhibitors, can be effective for some people with thymoma.

Overall, the prognosis for thymoma is generally good, with a 5-year survival rate of about 70% for people with localized disease. However, the prognosis can vary depending on the stage and aggressiveness of the tumor, as well as the effectiveness of treatment.

A parasitic disease caused by a protozoan of the genus Leishmania, which is transmitted to humans by the bite of an infected sandfly. The most common form of the disease is characterized by skin lesions, which may be painful and disfiguring.

Other forms of leishmaniasis include:

1. Visceral leishmaniasis (kala-azar): A severe and potentially fatal form of the disease that affects several internal organs, including the spleen, liver, and bone marrow.
2. Mucocutaneous leishmaniasis: A form of the disease characterized by skin lesions and mucosal involvement, such as nose ulcers and mouth sores.
3. Diffuse cutaneous leishmaniasis: A form of the disease characterized by widespread skin involvement, often with a diffuse, papular rash.
4. Recidivans leishmaniasis: A form of the disease characterized by repeated episodes of skin lesions, often triggered by exposure to sandflies.

Symptoms of cutaneous leishmaniasis may include:

* Skin lesions, which may be painful and disfiguring
* Swelling of the affected limb
* Fever
* Fatigue
* Weight loss

Diagnosis is made by identifying the parasite in a skin scraping or biopsy specimen. Treatment typically involves antiparasitic medications, such as pentavalent antimonials or amphotericin B.

Preventive measures include avoiding sandfly bites, wearing protective clothing and insect repellents, and using screens on windows and doors to prevent sandflies from entering homes.

There are several causes of hypergammaglobulinemia, including:

1. Chronic infections: Prolonged infections can cause an increase in the production of immunoglobulins to fight off the infection.
2. Autoimmune disorders: Conditions such as rheumatoid arthritis, lupus, and multiple sclerosis can cause the immune system to produce excessive amounts of antibodies.
3. Cancer: Some types of cancer, such as Hodgkin's disease and non-Hodgkin's lymphoma, can cause an increase in immunoglobulin production.
4. Genetic disorders: Certain genetic conditions, such as X-linked agammaglobulinemia, can lead to a deficiency or excess of immunoglobulins.
5. Medications: Certain medications, such as corticosteroids and chemotherapy drugs, can suppress the immune system and reduce the production of immunoglobulins.

Symptoms of hypergammaglobulinemia can include:

1. Infections: Recurring infections are a common symptom of hypergammaglobulinemia, as the excessive amount of antibodies can make it difficult for the body to fight off infections effectively.
2. Fatigue: Chronic infections and inflammation can cause fatigue and weakness.
3. Weight loss: Recurring infections and chronic inflammation can lead to weight loss and malnutrition.
4. Swollen lymph nodes: Enlarged lymph nodes are a common symptom of hypergammaglobulinemia, as the body tries to fight off infections.
5. Fever: Recurring fevers can be a symptom of hypergammaglobulinemia, as the body tries to fight off infections.
6. Night sweats: Excessive sweating at night can be a symptom of hypergammaglobulinemia.
7. Skin rashes: Certain types of skin rashes can be a symptom of hypergammaglobulinemia, such as a rash caused by allergic reactions to medications or infections.
8. Joint pain: Pain and stiffness in the joints can be a symptom of hypergammaglobulinemia, particularly if the excessive amount of antibodies is causing inflammation in the joints.
9. Headaches: Chronic headaches can be a symptom of hypergammaglobulinemia, particularly if the excessive amount of antibodies is causing inflammation in the brain or other parts of the body.
10. Swollen liver and spleen: Enlarged liver and spleen can be a symptom of hypergammaglobulinemia, as the body tries to filter out excess antibodies and fight off infections.

It is important to note that these symptoms can also be caused by other medical conditions, so it is essential to consult a healthcare professional for proper diagnosis and treatment. A healthcare professional may perform blood tests and other diagnostic procedures to determine the underlying cause of the symptoms and develop an appropriate treatment plan. Treatment for hypergammaglobulinemia typically involves addressing the underlying cause of the condition, such as infections, allergies, or autoimmune disorders, and may include medications to reduce inflammation and suppress the immune system.

The symptoms of FIV can be similar to those of HIV in humans, including weight loss, poor appetite, swollen lymph nodes, and chronic infections. However, FIV-infected cats may also experience neurological symptoms such as seizures, paralysis, and behavioral changes.

There is no cure for FIV, but antiretroviral medications can help manage the symptoms and slow the progression of the disease. Secondary infections and diseases can also be treated with appropriate medication.

Prevention of FIV involves avoiding exposure to infected saliva, typically through deep bite wounds or close contact with an infected cat. Adopting a cat from a shelter or breeder that tests for FIV and keeping your cat indoors can reduce the risk of infection. Vaccination against FIV is available but not considered effective.

The diagnosis of FIV is based on a combination of physical examination, medical history, and laboratory tests such as blood tests or PCR (polymerase chain reaction) tests to detect the virus. Confirmation of the diagnosis is typically made by measuring the level of antibodies against FIV in the cat's blood.

Treatment for FIV-infected cats involves managing the symptoms and preventing secondary infections. Antiretroviral medications may be prescribed to reduce the viral load and slow the progression of the disease. Supportive care such as antibiotics, anti-inflammatory drugs, and nutritional supplements may also be provided to manage symptoms and improve the cat's quality of life.

In summary, Feline Acquired Immunodeficiency Syndrome (AIDS) is a disease that affects cats caused by the Feline Immunodeficiency Virus (FIV). It is important to be aware of the risk factors and symptoms of FIV and seek veterinary care if you suspect your cat may have been infected. With proper diagnosis, treatment, and care, cats with FIV can live a happy and comfortable life for years.

People with SCID are extremely susceptible to infections, particularly those caused by viruses, and often develop symptoms shortly after birth. These may include diarrhea, vomiting, fever, and failure to gain weight or grow at the expected rate. Without treatment, SCID can lead to life-threatening infections and can be fatal within the first year of life.

Treatment for SCID typically involves bone marrow transplantation or enzyme replacement therapy. Bone marrow transplantation involves replacing the patient's faulty immune system with healthy cells from a donor, while enzyme replacement therapy involves replacing the missing or dysfunctional enzymes that cause the immune deficiency. Both of these treatments can help restore the patient's immune system and improve their quality of life.

In summary, severe combined immunodeficiency (SCID) is a rare genetic disorder that impairs the body's ability to fight infections and can be fatal without treatment. Treatment options include bone marrow transplantation and enzyme replacement therapy.

There are several types of dermatitis, including:

1. Atopic dermatitis: a chronic condition characterized by dry, itchy skin and a tendency to develop allergies.
2. Contact dermatitis: a localized reaction to an allergen or irritant that comes into contact with the skin.
3. Seborrheic dermatitis: a condition characterized by redness, itching, and flaking skin on the scalp, face, or body.
4. Psoriasis: a chronic condition characterized by thick, scaly patches on the skin.
5. Cutaneous lupus erythematosus: a chronic autoimmune disorder that can cause skin rashes and lesions.
6. Dermatitis herpetiformis: a rare condition characterized by itchy blisters or rashes on the skin.

Dermatitis can be diagnosed through a physical examination, medical history, and sometimes laboratory tests such as patch testing or biopsy. Treatment options for dermatitis depend on the cause and severity of the condition, but may include topical creams or ointments, oral medications, phototherapy, or lifestyle changes such as avoiding allergens or irritants.

Myeloid leukemia can be classified into several subtypes based on the type of cell involved and the degree of maturity of the abnormal cells. The most common types of myeloid leukemia include:

1. Acute Myeloid Leukemia (AML): This is the most aggressive form of myeloid leukemia, characterized by a rapid progression of immature cells that do not mature or differentiate into normal cells. AML can be further divided into several subtypes based on the presence of certain genetic mutations or chromosomal abnormalities.
2. Chronic Myeloid Leukemia (CML): This is a slower-growing form of myeloid leukemia, characterized by the presence of a genetic abnormality known as the Philadelphia chromosome. CML is typically treated with targeted therapies or bone marrow transplantation.
3. Myelodysplastic Syndrome (MDS): This is a group of disorders characterized by the impaired development of immature blood cells in the bone marrow. MDS can progress to AML if left untreated.
4. Chronic Myelomonocytic Leukemia (CMML): This is a rare form of myeloid leukemia that is characterized by the accumulation of immature monocytes in the blood and bone marrow. CMML can be treated with chemotherapy or bone marrow transplantation.

The symptoms of myeloid leukemia can vary depending on the subtype and severity of the disease. Common symptoms include fatigue, weakness, fever, night sweats, and weight loss. Diagnosis is typically made through a combination of physical examination, blood tests, and bone marrow biopsy. Treatment options for myeloid leukemia can include chemotherapy, targeted therapies, bone marrow transplantation, and supportive care to manage symptoms and prevent complications. The prognosis for myeloid leukemia varies depending on the subtype of the disease and the patient's overall health. With current treatments, many patients with myeloid leukemia can achieve long-term remission or even be cured.

The term splenomegaly is used to describe any condition that results in an increase in the size of the spleen, regardless of the underlying cause. This can be caused by a variety of factors, such as infection, inflammation, cancer, or genetic disorders.

Splenomegaly can be diagnosed through a physical examination, where the doctor may feel the enlarged spleen during an abdominal palpation. Imaging tests, such as ultrasound, computed tomography (CT) scans, or magnetic resonance imaging (MRI), may also be used to confirm the diagnosis and evaluate the extent of the splenomegaly.

Treatment for splenomegaly depends on the underlying cause. For example, infections such as malaria or mononucleosis are treated with antibiotics, while cancerous conditions may require surgical intervention or chemotherapy. In some cases, the spleen may need to be removed, a procedure known as splenectomy.

In conclusion, splenomegaly is an abnormal enlargement of the spleen that can be caused by various factors and requires prompt medical attention for proper diagnosis and treatment.

Anaplastic large cell lymphoma (ALCL) is a rare subtype of non-Hodgkin's lymphoma that was first identified in 1985. It typically affects the skin, particularly the legs, and can present with symptoms such as swelling, redness, and itching. Less common sites include the lymph nodes, liver, spleen, bone marrow, or gastrointestinal tract.

Symptoms of ALCL may also include fever, night sweats, weight loss, fatigue, and swollen lymph nodes. The cancer cells are typically large and have an "anaplastic" appearance under a microscope, with prominent nucleoli and abundant cytoplasm.

Treatment for ALCL usually involves chemotherapy, radiation therapy, or a combination of both. In some cases, bone marrow or stem cell transplantation may be necessary. The prognosis for ALCL varies depending on the stage and location of the cancer, but overall it is considered to be a relatively rare and aggressive form of non-Hodgkin's lymphoma.

In summary, anaplastic large cell lymphoma (ALCL) is a rare and aggressive subtype of non-Hodgkin's lymphoma that primarily affects the skin, but can also involve other lymphoid tissues and organs. It is characterized by large, anaplastic cells with prominent nucleoli and abundant cytoplasm, and typically presents with symptoms such as swelling, redness, itching, fever, night sweats, weight loss, and fatigue. Treatment usually involves chemotherapy, radiation therapy, or a combination of both, and the prognosis varies depending on the stage and location of the cancer.

There are several types of hypersensitivity reactions, including:

1. Type I hypersensitivity: This is also known as immediate hypersensitivity and occurs within minutes to hours after exposure to the allergen. It is characterized by the release of histamine and other chemical mediators from immune cells, leading to symptoms such as hives, itching, swelling, and difficulty breathing. Examples of Type I hypersensitivity reactions include allergies to pollen, dust mites, or certain foods.
2. Type II hypersensitivity: This is also known as cytotoxic hypersensitivity and occurs within days to weeks after exposure to the allergen. It is characterized by the immune system producing antibodies against specific proteins on the surface of cells, leading to their destruction. Examples of Type II hypersensitivity reactions include blood transfusion reactions and serum sickness.
3. Type III hypersensitivity: This is also known as immune complex hypersensitivity and occurs when antigens bind to immune complexes, leading to the formation of deposits in tissues. Examples of Type III hypersensitivity reactions include rheumatoid arthritis and systemic lupus erythematosus.
4. Type IV hypersensitivity: This is also known as delayed-type hypersensitivity and occurs within weeks to months after exposure to the allergen. It is characterized by the activation of T cells, leading to inflammation and tissue damage. Examples of Type IV hypersensitivity reactions include contact dermatitis and toxic epidermal necrolysis.

The diagnosis of hypersensitivity often involves a combination of medical history, physical examination, laboratory tests, and elimination diets or challenges. Treatment depends on the specific type of hypersensitivity reaction and may include avoidance of the allergen, medications such as antihistamines or corticosteroids, and immunomodulatory therapy.

Psoriasis can affect any part of the body, including the scalp, elbows, knees, and lower back. The symptoms of psoriasis can vary in severity, and the condition can have a significant impact on quality of life. In addition to physical discomfort, psoriasis can also cause emotional distress and stigma.

There is no cure for psoriasis, but there are several treatment options available, including topical creams and ointments, light therapy, and systemic medications such as biologic drugs. With proper treatment, many people with psoriasis are able to manage their symptoms and improve their quality of life.

Psoriasis is relatively common, affecting approximately 2-3% of the global population, with a higher prevalence in Caucasians than in other races. It can occur at any age, but typically starts in the late teenage years or early adulthood. Psoriasis is often associated with other health conditions, such as diabetes, heart disease, and depression.

Overall, psoriasis is a complex and multifactorial condition that requires a comprehensive approach to management, including both physical and emotional support. With appropriate treatment and self-care, people with psoriasis can lead full and active lives.

Pathologic neovascularization can be seen in a variety of conditions, including cancer, diabetic retinopathy, and age-related macular degeneration. In cancer, for example, the formation of new blood vessels can help the tumor grow and spread to other parts of the body. In diabetic retinopathy, the growth of new blood vessels in the retina can cause vision loss and other complications.

There are several different types of pathologic neovascularization, including:

* Angiosarcoma: a type of cancer that arises from the cells lining blood vessels
* Hemangiomas: benign tumors that are composed of blood vessels
* Cavernous malformations: abnormal collections of blood vessels in the brain or other parts of the body
* Pyogenic granulomas: inflammatory lesions that can form in response to trauma or infection.

The diagnosis of pathologic neovascularization is typically made through a combination of physical examination, imaging studies (such as ultrasound, CT scans, or MRI), and biopsy. Treatment options vary depending on the underlying cause of the condition, but may include medications, surgery, or radiation therapy.

In summary, pathologic neovascularization is a process that occurs in response to injury or disease, and it can lead to serious complications. It is important for healthcare professionals to be aware of this condition and its various forms in order to provide appropriate diagnosis and treatment.

The symptoms of PRE-B-ALL can include fever, fatigue, night sweats, weight loss, and swollen lymph nodes. The cancer can also spread to other parts of the body, such as the central nervous system, spleen, and bones.

PRE-B-ALL is most commonly seen in children, but it can also occur in adults. It is a rare cancer, accounting for only about 5% of all childhood leukemias and less than 1% of all adult leukemias.

The exact cause of PRE-B-ALL is not known, but it is believed to be linked to genetic mutations that occur during fetal development or early childhood. Some risk factors that may increase the likelihood of developing PRE-B-ALL include:

1. Genetic disorders, such as Down syndrome or Fanconi anemia.
2. Exposure to radiation or certain chemicals during pregnancy or early childhood.
3. Infections, such as HIV or Epstein-Barr virus.
4. Family history of PRE-B-ALL or other blood cancers.

To diagnose PRE-B-ALL, a bone marrow biopsy and aspiration are typically performed to collect a sample of cells for analysis. Additional tests, such as flow cytometry, immunophenotyping, and cytogenetic analysis, may also be conducted to confirm the diagnosis and identify any specific genetic abnormalities.

Treatment for PRE-B-ALL usually involves a combination of chemotherapy and/or bone marrow transplantation. The prognosis for PRE-B-ALL varies depending on the patient's age, overall health, and the specific genetic abnormalities present in the cancer cells. With current treatments, the 5-year survival rate for PRE-B-ALL is approximately 70-80%. However, the disease can sometimes relapse, and patients may require ongoing monitoring and treatment to prevent relapse and manage any long-term complications.

AML is a fast-growing and aggressive form of leukemia that can spread to other parts of the body through the bloodstream. It is most commonly seen in adults over the age of 60, but it can also occur in children.

There are several subtypes of AML, including:

1. Acute promyelocytic leukemia (APL): This is a subtype of AML that is characterized by the presence of a specific genetic abnormality called the PML-RARA fusion gene. It is usually responsive to treatment with chemotherapy and has a good prognosis.
2. Acute myeloid leukemia, not otherwise specified (NOS): This is the most common subtype of AML and does not have any specific genetic abnormalities. It can be more difficult to treat and has a poorer prognosis than other subtypes.
3. Chronic myelomonocytic leukemia (CMML): This is a subtype of AML that is characterized by the presence of too many immature white blood cells called monocytes in the blood and bone marrow. It can progress slowly over time and may require ongoing treatment.
4. Juvenile myeloid leukemia (JMML): This is a rare subtype of AML that occurs in children under the age of 18. It is characterized by the presence of too many immature white blood cells called blasts in the blood and bone marrow.

The symptoms of AML can vary depending on the subtype and the severity of the disease, but they may include:

* Fatigue
* Weakness
* Shortness of breath
* Pale skin
* Easy bruising or bleeding
* Swollen lymph nodes, liver, or spleen
* Bone pain
* Headache
* Confusion or seizures

AML is diagnosed through a combination of physical examination, medical history, and diagnostic tests such as:

1. Complete blood count (CBC): This test measures the number and types of cells in the blood, including red blood cells, white blood cells, and platelets.
2. Bone marrow biopsy: This test involves removing a small sample of bone marrow tissue from the hipbone or breastbone to examine under a microscope for signs of leukemia cells.
3. Genetic testing: This test can help identify specific genetic abnormalities that are associated with AML.
4. Immunophenotyping: This test uses antibodies to identify the surface proteins on leukemia cells, which can help diagnose the subtype of AML.
5. Cytogenetics: This test involves staining the bone marrow cells with dyes to look for specific changes in the chromosomes that are associated with AML.

Treatment for AML typically involves a combination of chemotherapy, targeted therapy, and in some cases, bone marrow transplantation. The specific treatment plan will depend on the subtype of AML, the patient's age and overall health, and other factors. Some common treatments for AML include:

1. Chemotherapy: This involves using drugs to kill cancer cells. The most commonly used chemotherapy drugs for AML are cytarabine (Ara-C) and anthracyclines such as daunorubicin (DaunoXome) and idarubicin (Idamycin).
2. Targeted therapy: This involves using drugs that specifically target the genetic abnormalities that are causing the cancer. Examples of targeted therapies used for AML include midostaurin (Rydapt) and gilteritinib (Xospata).
3. Bone marrow transplantation: This involves replacing the diseased bone marrow with healthy bone marrow from a donor. This is typically done after high-dose chemotherapy to destroy the cancer cells.
4. Supportive care: This includes treatments to manage symptoms and side effects of the disease and its treatment, such as anemia, infection, and bleeding. Examples of supportive care for AML include blood transfusions, antibiotics, and platelet transfusions.
5. Clinical trials: These are research studies that involve testing new treatments for AML. Participating in a clinical trial may give patients access to innovative therapies that are not yet widely available.

It's important to note that the treatment plan for AML is highly individualized, and the specific treatments used will depend on the patient's age, overall health, and other factors. Patients should work closely with their healthcare team to determine the best course of treatment for their specific needs.

Neoplastic metastasis can occur in any type of cancer but are more common in solid tumors such as carcinomas (breast, lung, colon). It is important for cancer diagnosis and prognosis because metastasis indicates that the cancer has spread beyond its original site and may be more difficult to treat.

Metastases can appear at any distant location but commonly found sites include the liver, lungs, bones, brain, and lymph nodes. The presence of metastases indicates a higher stage of cancer which is associated with lower survival rates compared to localized cancer.

There are different types of Breast Neoplasms such as:

1. Fibroadenomas: These are benign tumors that are made up of glandular and fibrous tissues. They are usually small and round, with a smooth surface, and can be moved easily under the skin.

2. Cysts: These are fluid-filled sacs that can develop in both breast tissue and milk ducts. They are usually benign and can disappear on their own or be drained surgically.

3. Ductal Carcinoma In Situ (DCIS): This is a precancerous condition where abnormal cells grow inside the milk ducts. If left untreated, it can progress to invasive breast cancer.

4. Invasive Ductal Carcinoma (IDC): This is the most common type of breast cancer and starts in the milk ducts but grows out of them and invades surrounding tissue.

5. Invasive Lobular Carcinoma (ILC): It originates in the milk-producing glands (lobules) and grows out of them, invading nearby tissue.

Breast Neoplasms can cause various symptoms such as a lump or thickening in the breast or underarm area, skin changes like redness or dimpling, change in size or shape of one or both breasts, discharge from the nipple, and changes in the texture or color of the skin.

Treatment options for Breast Neoplasms may include surgery such as lumpectomy, mastectomy, or breast-conserving surgery, radiation therapy which uses high-energy beams to kill cancer cells, chemotherapy using drugs to kill cancer cells, targeted therapy which uses drugs or other substances to identify and attack cancer cells while minimizing harm to normal cells, hormone therapy, immunotherapy, and clinical trials.

It is important to note that not all Breast Neoplasms are cancerous; some are benign (non-cancerous) tumors that do not spread or grow.

The symptoms of infectious mononucleosis can vary in severity but typically include:

* Fatigue
* Fever
* Sore throat
* Swollen lymph nodes in the neck and armpits
* Enlarged spleen
* Headache
* Muscle weakness
* Rash
* Swollen liver or spleen

Infectious mononucleosis is usually diagnosed through a combination of physical examination, blood tests, and other laboratory tests. Treatment focuses on relieving symptoms and allowing the body to fight the infection on its own.

Prognosis for infectious mononucleosis is generally good, but it can take several weeks to recover fully. Complications are rare but can include inflammation of the spleen, liver disease, and a condition called splenomegaly (enlargement of the spleen).

Prevention includes avoiding close contact with people who have mononucleosis, washing hands frequently, and not sharing eating or drinking utensils. There is no vaccine available to protect against infectious mononucleosis.

The condition typically affects older adults and is more common in men than women. The exact cause of Sezary syndrome is not known, but it is believed to be linked to genetic mutations and environmental factors.

Symptoms of Sezary syndrome can include:

* Skin rashes, lesions, or nodules
* Itching, redness, and dryness of the skin
* Fatigue
* Fever
* Weight loss
* Swollen lymph nodes
* Enlarged spleen

Sezary syndrome is diagnosed through a combination of physical examination, medical history, and laboratory tests such as biopsies, blood tests, and imaging studies. Treatment options for Sezary syndrome include:

* Chemotherapy
* Radiation therapy
* Phototherapy
* Targeted therapy

Overall, Sezary syndrome is a rare and aggressive form of CTCL that can have severe symptoms and affect multiple organs. Early diagnosis and treatment are essential to improve outcomes for patients with this condition.

The symptoms of CVID can vary from person to person and may include:

1. Frequent or recurring infections, such as sinus infections, ear infections, and pneumonia.
2. Poor response to vaccines.
3. Delayed growth and development in children.
4. Autoimmune disorders, such as thyroiditis or arthritis.
5. Increased risk of developing certain types of cancer, such as lymphoma.

CVID is caused by mutations in several genes that are involved in the immune system. These genes play a role in the development and function of immune cells, such as T cells and B cells. The exact cause of CVID is often not known, but it can be inherited or acquired through genetic mutations.

There is no cure for CVID, but treatment can help manage the symptoms and prevent complications. Treatment typically involves antibiotics to fight off infections, immunoglobulin replacement therapy to boost the immune system, and medication to manage autoimmune disorders. In some cases, a bone marrow transplant may be recommended.

The prognosis for CVID varies depending on the severity of the disorder and the presence of any complications. With proper treatment, many people with CVID can lead normal lives and have a good quality of life. However, some individuals may experience ongoing health problems and a higher risk of developing certain types of cancer.

Adult T-cell leukemia/lymphoma (ATLL) is a rare type of cancer that affects the immune system. It is caused by the human T-lymphotropic virus type 1 (HTLV-1), which is transmitted through breastfeeding or blood transfusions. ATLL typically affects adults and can cause a range of symptoms, including fever, fatigue, weight loss, and swollen lymph nodes.

If you suspect that you or someone you know may have ATLL, it is important to seek medical attention as soon as possible. A healthcare provider will perform a physical examination and order diagnostic tests to determine if HTLV-1 is present in the body. Diagnostic tests for ATLL may include blood tests, imaging studies, and biopsies.

There are several treatment options available for ATLL, including chemotherapy, radiation therapy, and bone marrow transplantation. The choice of treatment will depend on the stage and severity of the disease, as well as the patient's overall health. In some cases, a combination of treatments may be used to achieve the best possible outcome.

Unfortunately, the prognosis for ATLL is poor, with a five-year survival rate of less than 30%. However, early detection and treatment can improve the chances of survival. It is important to note that there is currently no cure for ATLL, but ongoing research is exploring new treatments and therapies to improve outcomes for patients with this disease.

In conclusion, ATLL is a rare and aggressive form of cancer that affects the immune system. It is caused by the HTLV-1 virus and can progress slowly over several years before symptoms appear. If you suspect that you or someone you know may have ATLL, it is important to seek medical attention as soon as possible for proper diagnosis and treatment. While the prognosis is poor, early detection and treatment can improve survival rates. Ongoing research is exploring new treatments and therapies to improve outcomes for patients with ATLL.

Explanation: Genetic predisposition to disease is influenced by multiple factors, including the presence of inherited genetic mutations or variations, environmental factors, and lifestyle choices. The likelihood of developing a particular disease can be increased by inherited genetic mutations that affect the functioning of specific genes or biological pathways. For example, inherited mutations in the BRCA1 and BRCA2 genes increase the risk of developing breast and ovarian cancer.

The expression of genetic predisposition to disease can vary widely, and not all individuals with a genetic predisposition will develop the disease. Additionally, many factors can influence the likelihood of developing a particular disease, such as environmental exposures, lifestyle choices, and other health conditions.

Inheritance patterns: Genetic predisposition to disease can be inherited in an autosomal dominant, autosomal recessive, or multifactorial pattern, depending on the specific disease and the genetic mutations involved. Autosomal dominant inheritance means that a single copy of the mutated gene is enough to cause the disease, while autosomal recessive inheritance requires two copies of the mutated gene. Multifactorial inheritance involves multiple genes and environmental factors contributing to the development of the disease.

Examples of diseases with a known genetic predisposition:

1. Huntington's disease: An autosomal dominant disorder caused by an expansion of a CAG repeat in the Huntingtin gene, leading to progressive neurodegeneration and cognitive decline.
2. Cystic fibrosis: An autosomal recessive disorder caused by mutations in the CFTR gene, leading to respiratory and digestive problems.
3. BRCA1/2-related breast and ovarian cancer: An inherited increased risk of developing breast and ovarian cancer due to mutations in the BRCA1 or BRCA2 genes.
4. Sickle cell anemia: An autosomal recessive disorder caused by a point mutation in the HBB gene, leading to defective hemoglobin production and red blood cell sickling.
5. Type 1 diabetes: An autoimmune disease caused by a combination of genetic and environmental factors, including multiple genes in the HLA complex.

Understanding the genetic basis of disease can help with early detection, prevention, and treatment. For example, genetic testing can identify individuals who are at risk for certain diseases, allowing for earlier intervention and preventive measures. Additionally, understanding the genetic basis of a disease can inform the development of targeted therapies and personalized medicine."


Pulmonary tuberculosis typically affects the lungs but can also spread to other parts of the body, such as the brain, kidneys, or spine. The symptoms of pulmonary TB include coughing for more than three weeks, chest pain, fatigue, fever, night sweats, and weight loss.

Pulmonary tuberculosis is diagnosed by a combination of physical examination, medical history, laboratory tests, and radiologic imaging, such as chest X-rays or computed tomography (CT) scans. Treatment for pulmonary TB usually involves a combination of antibiotics and medications to manage symptoms.

Preventive measures for pulmonary tuberculosis include screening for latent TB infection in high-risk populations, such as healthcare workers and individuals with HIV/AIDS, and vaccination with the bacillus Calmette-Guérin (BCG) vaccine in countries where it is available.

Overall, pulmonary tuberculosis is a serious and potentially life-threatening disease that requires prompt diagnosis and treatment to prevent complications and death.

There are several types of lung neoplasms, including:

1. Adenocarcinoma: This is the most common type of lung cancer, accounting for approximately 40% of all lung cancers. It is a malignant tumor that originates in the glands of the respiratory tract and can be found in any part of the lung.
2. Squamous cell carcinoma: This type of lung cancer accounts for approximately 25% of all lung cancers and is more common in men than women. It is a malignant tumor that originates in the squamous cells lining the airways of the lungs.
3. Small cell lung cancer (SCLC): This is a highly aggressive form of lung cancer that accounts for approximately 15% of all lung cancers. It is often found in the central parts of the lungs and can spread quickly to other parts of the body.
4. Large cell carcinoma: This is a rare type of lung cancer that accounts for only about 5% of all lung cancers. It is a malignant tumor that originates in the large cells of the respiratory tract and can be found in any part of the lung.
5. Bronchioalveolar carcinoma (BAC): This is a rare type of lung cancer that originates in the cells lining the airways and alveoli of the lungs. It is more common in women than men and tends to affect older individuals.
6. Lymphangioleiomyomatosis (LAM): This is a rare, progressive, and often fatal lung disease that primarily affects women of childbearing age. It is characterized by the growth of smooth muscle-like cells in the lungs and can lead to cysts, lung collapse, and respiratory failure.
7. Hamartoma: This is a benign tumor that originates in the tissue of the lungs and is usually found in children. It is characterized by an overgrowth of normal lung tissue and can be treated with surgery.
8. Secondary lung cancer: This type of cancer occurs when cancer cells from another part of the body spread to the lungs through the bloodstream or lymphatic system. It is more common in people who have a history of smoking or exposure to other carcinogens.
9. Metastatic cancer: This type of cancer occurs when cancer cells from another part of the body spread to the lungs through the bloodstream or lymphatic system. It is more common in people who have a history of smoking or exposure to other carcinogens.
10. Mesothelioma: This is a rare and aggressive form of cancer that originates in the lining of the lungs or abdomen. It is caused by asbestos exposure and can be treated with surgery, chemotherapy, and radiation therapy.

Lung diseases can also be classified based on their cause, such as:

1. Infectious diseases: These are caused by bacteria, viruses, or other microorganisms and can include pneumonia, tuberculosis, and bronchitis.
2. Autoimmune diseases: These are caused by an overactive immune system and can include conditions such as sarcoidosis and idiopathic pulmonary fibrosis.
3. Genetic diseases: These are caused by inherited mutations in genes that affect the lungs and can include cystic fibrosis and primary ciliary dyskinesia.
4. Environmental diseases: These are caused by exposure to harmful substances such as tobacco smoke, air pollution, and asbestos.
5. Radiological diseases: These are caused by exposure to ionizing radiation and can include conditions such as radiographic breast cancer and lung cancer.
6. Vascular diseases: These are caused by problems with the blood vessels in the lungs and can include conditions such as pulmonary embolism and pulmonary hypertension.
7. Tumors: These can be benign or malignant and can include conditions such as lung metastases and lung cancer.
8. Trauma: This can include injuries to the chest or lungs caused by accidents or other forms of trauma.
9. Congenital diseases: These are present at birth and can include conditions such as bronchopulmonary foregut malformations and congenital cystic adenomatoid malformation.

Each type of lung disease has its own set of symptoms, diagnosis, and treatment options. It is important to seek medical attention if you experience any persistent or severe respiratory symptoms, as early diagnosis and treatment can improve outcomes and quality of life.

These animal models allow researchers to study the underlying causes of arthritis, test new treatments and therapies, and evaluate their effectiveness in a controlled environment before moving to human clinical trials. Experimental arthritis models are used to investigate various aspects of the disease, including its pathophysiology, immunogenicity, and potential therapeutic targets.

Some common experimental arthritis models include:

1. Collagen-induced arthritis (CIA): This model is induced in mice by immunizing them with type II collagen, which leads to an autoimmune response and inflammation in the joints.
2. Rheumatoid arthritis (RA) models: These models are developed by transferring cells from RA patients into immunodeficient mice, which then develop arthritis-like symptoms.
3. Osteoarthritis (OA) models: These models are induced in animals by subjecting them to joint injury or overuse, which leads to degenerative changes in the joints and bone.
4. Psoriatic arthritis (PsA) models: These models are developed by inducing psoriasis in mice, which then develop arthritis-like symptoms.

Experimental arthritis models have contributed significantly to our understanding of the disease and have helped to identify potential therapeutic targets for the treatment of arthritis. However, it is important to note that these models are not perfect representations of human arthritis and should be used as tools to complement, rather than replace, human clinical trials.

Pre-B ALL is characterized by the abnormal growth of immature white blood cells called B lymphocytes. These cells are produced in the bone marrow and are normally present in the blood. In Pre-B ALL, the abnormal B cells accumulate in the bone marrow, blood, and other organs, crowding out normal cells and causing a variety of symptoms.

The symptoms of Pre-B ALL can vary depending on the individual patient, but may include:

* Fatigue
* Easy bruising or bleeding
* Frequent infections
* Swollen lymph nodes
* Enlarged liver or spleen
* Bone pain
* Headaches
* Confusion or seizures (in severe cases)

Pre-B ALL is most commonly diagnosed in children, but it can also occur in adults. Treatment typically involves a combination of chemotherapy and sometimes bone marrow transplantation. The prognosis for Pre-B ALL is generally good, especially in children, with a high survival rate if treated promptly and effectively. However, the cancer can be more difficult to treat in adults, and the prognosis may be less favorable.

Overall, Pre-B ALL is a rare and aggressive form of leukemia that requires prompt and specialized treatment to improve outcomes for patients.

The symptoms of dermatitis, allergic contact can vary depending on the severity of the reaction, but may include:

* Redness and swelling of the affected area
* Itching, burning, or stinging sensations
* Small blisters or hives
* Thickening or scaling of the skin
* Crusting or oozing of fluid

Dermatitis, allergic contact can be caused by a variety of substances, including:

* Metals, such as nickel, chrome, and mercury
* Plastics, such as latex and polyethylene
* Certain chemicals, such as perfumes, dyes, and preservatives
* Plant extracts, such as poison ivy or poison oak
* Insect bites or stings

The diagnosis of dermatitis, allergic contact is typically made through a combination of physical examination, medical history, and patch testing. Patch testing involves applying small amounts of potential allergens to the skin and observing for any signs of an allergic reaction over a period of time.

Treatment for dermatitis, allergic contact typically focuses on removing the allergen from the affected area and providing relief from symptoms. This may include:

* Avoiding exposure to the allergen
* Applying topical creams or ointments to reduce inflammation and itching
* Taking oral medications, such as antihistamines or corticosteroids, to reduce symptoms
* In severe cases, hospitalization may be necessary to manage the reaction.

Preventative measures for dermatitis, allergic contact include:

* Avoiding exposure to potential allergens
* Wearing protective clothing or gloves when handling suspected allergens
* Using hypoallergenic products and avoiding fragrances and dyes
* Performing patch testing before introducing new substances into the environment.

It is important to seek medical attention if symptoms persist or worsen over time, as dermatitis, allergic contact can lead to complications such as infection or scarring. Early diagnosis and treatment can help prevent these complications and improve outcomes for patients with this condition.

Granulomas are formed in response to the presence of a foreign substance or an infection, and they serve as a protective barrier to prevent the spread of the infection and to isolate the offending agent. The granuloma is characterized by a central area of necrosis, surrounded by a ring of immune cells, including macrophages and T-lymphocytes.

Granulomas are commonly seen in a variety of inflammatory conditions, such as tuberculosis, leprosy, and sarcoidosis. They can also occur as a result of infections, such as bacterial or fungal infections, and in the context of autoimmune disorders, such as rheumatoid arthritis.

In summary, granuloma is a term used to describe a type of inflammatory lesion that is formed in response to the presence of a foreign substance or an infection, and serves as a protective barrier to prevent the spread of the infection and to isolate the offending agent.

There are several different types of uveitis, including:

1. Anterior uveitis: This type affects the front part of the eye and is the most common form of uveitis. It is often caused by an infection or injury.
2. Posterior uveitis: This type affects the back part of the eye and can be caused by a systemic disease such as sarcoidosis or juvenile idiopathic arthritis.
3. Intermediate uveitis: This type affects the middle layer of the eye and is often caused by an autoimmune disorder.
4. Panuveitis: This type affects the entire uvea and can be caused by a systemic disease such as vasculitis or Behçet's disease.

Symptoms of uveitis may include:

* Eye pain
* Redness and swelling in the eye
* Blurred vision
* Sensitivity to light
* Floaters (specks or cobwebs in your vision)
* Flashes of light

If you experience any of these symptoms, it is important to see an eye doctor as soon as possible. Uveitis can be diagnosed with a comprehensive eye exam, which may include imaging tests such as ultrasound or MRI. Treatment for uveitis depends on the cause and severity of the condition, but may include medication to reduce inflammation, antibiotics for infections, or surgery to remove any diseased tissue.

Early diagnosis and treatment are important to prevent complications such as cataracts, glaucoma, and blindness. If you have uveitis, it is important to follow your doctor's recommendations for treatment and monitoring to protect your vision.

There are several types of colonic neoplasms, including:

1. Adenomas: These are benign growths that are usually precursors to colorectal cancer.
2. Carcinomas: These are malignant tumors that arise from the epithelial lining of the colon.
3. Sarcomas: These are rare malignant tumors that arise from the connective tissue of the colon.
4. Lymphomas: These are cancers of the immune system that can affect the colon.

Colonic neoplasms can cause a variety of symptoms, including bleeding, abdominal pain, and changes in bowel habits. They are often diagnosed through a combination of medical imaging tests (such as colonoscopy or CT scan) and biopsy. Treatment for colonic neoplasms depends on the type and stage of the tumor, and may include surgery, chemotherapy, and/or radiation therapy.

Overall, colonic neoplasms are a common condition that can have serious consequences if left untreated. It is important for individuals to be aware of their risk factors and to undergo regular screening for colon cancer to help detect and treat any abnormal growths or tumors in the colon.

1. Tumor size and location: Larger tumors that have spread to nearby tissues or organs are generally considered more invasive than smaller tumors that are confined to the original site.
2. Cellular growth patterns: The way in which cancer cells grow and divide can also contribute to the overall invasiveness of a neoplasm. For example, cells that grow in a disorganized or chaotic manner may be more likely to invade surrounding tissues.
3. Mitotic index: The mitotic index is a measure of how quickly the cancer cells are dividing. A higher mitotic index is generally associated with more aggressive and invasive cancers.
4. Necrosis: Necrosis, or the death of cells, can be an indication of the level of invasiveness of a neoplasm. The presence of significant necrosis in a tumor is often a sign that the cancer has invaded surrounding tissues and organs.
5. Lymphovascular invasion: Cancer cells that have invaded lymphatic vessels or blood vessels are considered more invasive than those that have not.
6. Perineural invasion: Cancer cells that have invaded nerve fibers are also considered more invasive.
7. Histological grade: The histological grade of a neoplasm is a measure of how abnormal the cancer cells look under a microscope. Higher-grade cancers are generally considered more aggressive and invasive than lower-grade cancers.
8. Immunohistochemical markers: Certain immunohistochemical markers, such as Ki-67, can be used to evaluate the proliferative activity of cancer cells. Higher levels of these markers are generally associated with more aggressive and invasive cancers.

Overall, the degree of neoplasm invasiveness is an important factor in determining the likelihood of the cancer spreading to other parts of the body (metastasizing) and in determining the appropriate treatment strategy for the patient.

Hairy cell leukemia typically affects older adults, and it is usually slow-growing and progresses gradually over many years. Symptoms of hairy cell leukemia can include fatigue, weakness, weight loss, fever, night sweats, and swollen lymph nodes.

Hairy cell leukemia is diagnosed through a combination of physical examination, medical history, blood tests, and bone marrow biopsy. Treatment for hairy cell leukemia typically involves chemotherapy, radiation therapy, or a combination of both. In some cases, the disease may go into remission with treatment, but it can also be a chronic condition that requires ongoing management.

Prevention: There is no known prevention for hairy cell leukemia, as the cause of the disease is not fully understood. However, early detection and treatment can improve outcomes.

Prognosis: The prognosis for hairy cell leukemia varies depending on the individual patient and the aggressiveness of the disease. In general, the condition tends to be slow-growing and progresses gradually over many years. With appropriate treatment, some patients can achieve long-term remission or even be cured. However, in more advanced cases, the disease can be more difficult to treat and may have a poorer prognosis.

Symptoms: Symptoms of hairy cell leukemia can include fatigue, weakness, weight loss, fever, night sweats, and swollen lymph nodes. These symptoms can develop gradually over time, and they may be mild at first but become more severe as the disease progresses.

Treatment: Treatment for hairy cell leukemia typically involves chemotherapy, radiation therapy, or a combination of both. The specific treatment plan will depend on the individual patient and the severity of their condition. In some cases, watchful waiting may be appropriate, especially if the disease is not causing significant symptoms.

Lifestyle Changes: There are no lifestyle changes that can cure hairy cell leukemia, but they can help improve overall health and well-being. These changes may include eating a healthy diet, getting regular exercise, getting enough rest, and managing stress. In addition, avoiding exposure to certain chemicals and toxins may be beneficial for some patients.

Medications: There are several medications that can be used to treat hairy cell leukemia. These include chemotherapy drugs such as pentostatin and cladribine, which can help kill cancer cells and slow the progression of the disease. In addition, some patients may receive radiation therapy to help shrink swollen lymph nodes or other affected tissues.

Supportive Care: Supportive care is an important part of treatment for hairy cell leukemia. This type of care focuses on managing symptoms and improving quality of life, rather than directly targeting the cancer cells. Supportive care may include medications to manage pain, fatigue, or infection, as well as blood transfusions to help improve anemia.

Bone Marrow Transplant: In some cases, bone marrow transplant may be an option for patients with hairy cell leukemia. This involves replacing the patient's bone marrow with healthy cells from a donor, which can help cure the disease. However, this is typically reserved for patients who have not responded to other treatments or who have experienced significant complications from the disease.

Overall, the prognosis for hairy cell leukemia is generally good, with many patients experiencing a good response to treatment and a low risk of complications. However, it is important for patients to work closely with their healthcare team to develop a personalized treatment plan that meets their individual needs and helps them achieve the best possible outcome.

Hematologic neoplasms refer to abnormal growths or tumors that affect the blood, bone marrow, or lymphatic system. These types of cancer can originate from various cell types, including red blood cells, white blood cells, platelets, and lymphoid cells.

There are several subtypes of hematologic neoplasms, including:

1. Leukemias: Cancers of the blood-forming cells in the bone marrow, which can lead to an overproduction of immature or abnormal white blood cells, red blood cells, or platelets. Examples include acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).
2. Lymphomas: Cancers of the immune system, which can affect the lymph nodes, spleen, liver, or other organs. Examples include Hodgkin lymphoma and non-Hodgkin lymphoma.
3. Multiple myeloma: A cancer of the plasma cells in the bone marrow that can lead to an overproduction of abnormal plasma cells.
4. Myeloproliferative neoplasms: Cancers that affect the blood-forming cells in the bone marrow, leading to an overproduction of red blood cells, white blood cells, or platelets. Examples include polycythemia vera and essential thrombocythemia.
5. Myelodysplastic syndromes: Cancers that affect the blood-forming cells in the bone marrow, leading to an underproduction of normal blood cells.

The diagnosis of hematologic neoplasms typically involves a combination of physical examination, medical history, laboratory tests (such as complete blood counts and bone marrow biopsies), and imaging studies (such as CT scans or PET scans). Treatment options for hematologic neoplasms depend on the specific type of cancer, the severity of the disease, and the overall health of the patient. These may include chemotherapy, radiation therapy, stem cell transplantation, or targeted therapy with drugs that specifically target cancer cells.

* Nausea and vomiting
* Abdominal pain
* Diarrhea
* Fatigue
* Weakness
* Headache
* Dizziness
* Renal damage

In severe cases, cadmium poisoning can cause:

* Respiratory failure
* Cardiovascular collapse
* Seizures
* Coma
* Death

Treatment of cadmium poisoning usually involves supportive care, such as fluid replacement and management of symptoms. In cases of severe poisoning, hospitalization may be necessary and chelation therapy may be administered to remove the heavy metal from the body. Prevention of cadmium poisoning is key and this can be achieved through proper handling, storage and disposal of cadmium-containing materials, as well as using personal protective equipment during work with cadmium.

If you suspect that you or someone else has been exposed to cadmium, it is important to seek medical attention immediately. A healthcare professional will be able to assess the level and severity of exposure and provide appropriate treatment.

1. Common cold: A viral infection that affects the upper respiratory tract and causes symptoms such as sneezing, running nose, coughing, and mild fever.
2. Influenza (flu): A viral infection that can cause severe respiratory illness, including pneumonia, bronchitis, and sinus and ear infections.
3. Measles: A highly contagious viral infection that causes fever, rashes, coughing, and redness of the eyes.
4. Rubella (German measles): A mild viral infection that can cause fever, rashes, headache, and swollen lymph nodes.
5. Chickenpox: A highly contagious viral infection that causes fever, itching, and a characteristic rash of small blisters on the skin.
6. Herpes simplex virus (HSV): A viral infection that can cause genital herpes, cold sores, or other skin lesions.
7. Human immunodeficiency virus (HIV): A viral infection that attacks the immune system and can lead to acquired immunodeficiency syndrome (AIDS).
8. Hepatitis B: A viral infection that affects the liver, causing inflammation and damage to liver cells.
9. Hepatitis C: Another viral infection that affects the liver, often leading to chronic liver disease and liver cancer.
10. Ebola: A deadly viral infection that causes fever, vomiting, diarrhea, and internal bleeding.
11. SARS (severe acute respiratory syndrome): A viral infection that can cause severe respiratory illness, including pneumonia and respiratory failure.
12. West Nile virus: A viral infection that can cause fever, headache, and muscle pain, as well as more severe symptoms such as meningitis or encephalitis.

Viral infections can be spread through contact with an infected person or contaminated surfaces, objects, or insects such as mosquitoes. Prevention strategies include:

1. Practicing good hygiene, such as washing hands frequently and thoroughly.
2. Avoiding close contact with people who are sick.
3. Covering the mouth and nose when coughing or sneezing.
4. Avoiding sharing personal items such as towels or utensils.
5. Using condoms or other barrier methods during sexual activity.
6. Getting vaccinated against certain viral infections, such as HPV and hepatitis B.
7. Using insect repellents to prevent mosquito bites.
8. Screening blood products and organs for certain viruses before transfusion or transplantation.

Treatment for viral infections depends on the specific virus and the severity of the illness. Antiviral medications may be used to reduce the replication of the virus and alleviate symptoms. In severe cases, hospitalization may be necessary to provide supportive care such as intravenous fluids, oxygen therapy, or mechanical ventilation.

Prevention is key in avoiding viral infections, so taking the necessary precautions and practicing good hygiene can go a long way in protecting oneself and others from these common and potentially debilitating illnesses.

The term "Murine" refers to the fact that the condition occurs in mice and other rodents. "Acquired Immunodeficiency Syndrome" (AIDS) is a similar condition in humans caused by HIV. The similarity between MAIDS and AIDS lies in their shared origins as retroviral infections, but there are significant differences in the viruses themselves and the symptoms they cause.

Asthma can cause recurring episodes of wheezing, coughing, chest tightness, and shortness of breath. These symptoms occur when the muscles surrounding the airways contract, causing the airways to narrow and swell. This can be triggered by exposure to environmental allergens or irritants such as pollen, dust mites, pet dander, or respiratory infections.

There is no cure for asthma, but it can be managed with medication and lifestyle changes. Treatment typically includes inhaled corticosteroids to reduce inflammation, bronchodilators to open up the airways, and rescue medications to relieve symptoms during an asthma attack.

Asthma is a common condition that affects people of all ages, but it is most commonly diagnosed in children. According to the American Lung Association, more than 25 million Americans have asthma, and it is the third leading cause of hospitalization for children under the age of 18.

While there is no cure for asthma, early diagnosis and proper treatment can help manage symptoms and improve quality of life for those affected by the condition.

Recurrence can also refer to the re-emergence of symptoms in a previously treated condition, such as a chronic pain condition that returns after a period of remission.

In medical research, recurrence is often studied to understand the underlying causes of disease progression and to develop new treatments and interventions to prevent or delay its return.

The symptoms of mycosis fungoides can vary depending on the stage of the disease, but they may include:

* A rash or patches of skin that are red, itchy, and scaly
* Swollen lymph nodes, especially in the neck, armpits, or groin
* Fever, fatigue, or weight loss
* Enlarged liver or spleen
* Night sweats
* Itching or painless skin lesions

Mycosis fungoides can be difficult to diagnose because it can resemble other skin conditions such as eczema or psoriasis. A biopsy of the skin is usually needed to confirm the diagnosis. Treatment options for mycosis fungoides depend on the stage and severity of the disease, but may include:

* Topical medications or creams to treat mild cases
* Phototherapy with ultraviolet light to reduce inflammation and slow the growth of cancer cells
* Chemotherapy to kill cancer cells
* Radiation therapy to destroy cancer cells
* Targeted therapy using drugs that specifically target cancer cells
* Stem cell transplantation in severe cases.

The prognosis for mycosis fungoides is generally good if the disease is caught early and treated aggressively. However, the disease can be challenging to treat and may recur even after successful treatment. Ongoing research is focused on developing new and more effective treatments for this rare and complex condition.

Adenocarcinoma is a term used to describe a variety of different types of cancer that arise in glandular tissue, including:

1. Colorectal adenocarcinoma (cancer of the colon or rectum)
2. Breast adenocarcinoma (cancer of the breast)
3. Prostate adenocarcinoma (cancer of the prostate gland)
4. Pancreatic adenocarcinoma (cancer of the pancreas)
5. Lung adenocarcinoma (cancer of the lung)
6. Thyroid adenocarcinoma (cancer of the thyroid gland)
7. Skin adenocarcinoma (cancer of the skin)

The symptoms of adenocarcinoma depend on the location of the cancer and can include:

1. Blood in the stool or urine
2. Abdominal pain or discomfort
3. Changes in bowel habits
4. Unusual vaginal bleeding (in the case of endometrial adenocarcinoma)
5. A lump or thickening in the breast or elsewhere
6. Weight loss
7. Fatigue
8. Coughing up blood (in the case of lung adenocarcinoma)

The diagnosis of adenocarcinoma is typically made through a combination of imaging tests, such as CT scans, MRI scans, and PET scans, and a biopsy, which involves removing a sample of tissue from the affected area and examining it under a microscope for cancer cells.

Treatment options for adenocarcinoma depend on the location of the cancer and can include:

1. Surgery to remove the tumor
2. Chemotherapy, which involves using drugs to kill cancer cells
3. Radiation therapy, which involves using high-energy X-rays or other particles to kill cancer cells
4. Targeted therapy, which involves using drugs that target specific molecules on cancer cells to kill them
5. Immunotherapy, which involves using drugs that stimulate the immune system to fight cancer cells.

The prognosis for adenocarcinoma is generally good if the cancer is detected and treated early, but it can be more challenging to treat if the cancer has spread to other parts of the body.

The lymphocytes present in VUE are predominantly CD8+ T-cells then CD4. There is usually a ratio of 0.1 to 0.5 for CD4/CD8. The ...
Liu CC, Huang KJ, Lin YS, Yeh TM, Liu HS, Lei HY (October 2002). "Transient CD4/CD8 ratio inversion and aberrant immune ... CD4 expression and CD3 signaling". The EMBO Journal. 16 (4): 673-84. doi:10.1093/emboj/16.4.673. PMC 1169669. PMID 9049297. ...
Bronchoalveolar Lavage (BAL) findings coinciding with pneumonitis typically include a lymphocytosis with a low CD4:CD8 ratio. ...
CD4/CD8 ratios as well as the SASP phenotype. Altogether, these biomarkers may not be translationally relevant to clinical ...
"Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control". Am ...
AITL typically has the phenotype of a mixture of CD4+ and CD8+ T-cells, with a CD4:CD8 ratio greater than unity. Polyclonal ...
Arsenic exposure in small children distorts the ratio of T helper cells (CD4) to cytotoxic T cells (CD8), which are responsible ...
In at least one study the induced sputum ratio of CD4/CD8 and level of TNF was correlated to those in the lavage fluid. A ... A bronchoalveolar lavage can show an elevated (of at least 3.5) CD4/CD8 T cell ratio, which is indicative (but not proof) of ...
... and CD4:CD8 ratios in asymptomatic FIV-infected cats". Journal of Feline Medicine and Surgery. 10 (5): 423-430. doi:10.1016/j. ...
... reduced CD4:CD8 ratio, moderately high B cell counts, and mild neutropenia. Their neutropenia may be related to their chronic ... July 2013). "Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D". Science. 341 ( ... The disease is characterized by CD4 lymphopenia, severe chronic viral infections, and defective T-lymphocyte activation. ...
Mild defects in T-cell function can also be observed, in addition to an inverted CD4/CD8 ratio Once a diagnosis is made, the ...
... cd4 lymphocyte count MeSH G09.188.250.161.595.500.150.160 - cd4-cd8 ratio MeSH G09.188.250.161.700 - platelet count MeSH ... ventilation-perfusion ratio MeSH G09.772.765.925 - voice MeSH G09.772.765.925.960 - voice quality MeSH G09.772.765.962 - work ...
... cd4 lymphocyte count MeSH E05.200.500.195.107.595.500.150.160 - cd4-cd8 ratio MeSH E05.200.500.195.107.740 - platelet count ... odds ratio MeSH E05.318.740.600.700 - proportional hazards models MeSH E05.318.740.600.800 - risk MeSH E05.318.740.600.800.450 ...
... cd4 lymphocyte count MeSH G04.335.130.107.595.500.150.160 - cd4-cd8 ratio MeSH G04.335.130.107.740 - platelet count MeSH ...
... increased CD4:CD8 ratio) TSH-receptor antibodies (TSH-R Abs) This condition is commonly undiagnosed by physicians due to either ...
... cd4 lymphocyte count MeSH E01.450.375.107.595.500.150.160 - cd4-cd8 ratio MeSH E01.450.375.107.700 - platelet count MeSH ... waist-hip ratio MeSH E01.370.600.115.800 - somatotypes MeSH E01.370.600.120 - body temperature MeSH E01.370.600.225 - facial ... ventilation-perfusion ratio MeSH E01.370.386.700.660 - pulmonary ventilation MeSH E01.370.386.700.660.225 - forced expiratory ... E01.450.375.115 - blood coagulation tests MeSH E01.450.375.115.320 - international normalized ratio MeSH E01.450.375.115.600 - ...
... may express CD4, and usually do not express CD8. There is no standard treatment for MEITL. Most individuals have been treated ... MEITL has been seen more often in Asians and individuals of Hispanic descent, in males (male to female ratio of ~2 to 1), and ... CD8, and CD56; by their failure to express CD4, CD5, or CD30; and, in particular, by their overexpression of megakaryocyte- ... CD8, or CD56. Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS): PTCL-NOS is a heterogenous group of T cell ...
... binds CD4 and a chemokine receptor on the surface of a T helper cell to gain entry. The number of CD4 and CD8 T cells in blood ... Antibodies CD71/Transferrin receptor-1 CD13 marker for kidney disorder CD33 marker for AML treatment CD4+/CD8+ ratio Immune ... Two commonly used CD molecules are CD4 and CD8, which are, in general, used as markers for helper and cytotoxic T cells, ... In the example of CD4 & CD8, these molecules are critical in antigen recognition. Others (e.g., CD135) act as cell surface ...
TNF-α is produced by infected macrophages and the interaction between dendritic cells presenting the antigen to CD8 (T Killer ... Mortality in HIV-infected patients with cardiomyopathy is increased independently of CD4 count, age, sex, and HIV risk group. ... the hazard ratio is 3.4. Cardiomyopathy and encephalopathy are hypothesised to be linked by the HIV reservoir cells which are ... myocardial viral infection and was inversely correlated with CD4 count with antiretroviral therapy having no effect.[citation ...
... and correlates with both CD4:CD8 alterations and impaired dendritic cell function. Therefore, vaccination in earlier life ... ATP ratio and lower NAD/NADH ratio. Coenzyme NAD+ is reduced in various tissues in an age-dependent manner, and thus redox ... Huff WX, Kwon JH, Henriquez M, Fetcko K, Dey M (June 2019). "The Evolving Role of CD8+CD28− Immunosenescent T Cells in Cancer ... shift in the CD4+/CD8+ ratio the accumulation and clonal expansion of memory and effector T cells impaired development of CD4+ ...
IL-18 in combination with IL12 acts on CD4, CD8 T cells and NK cells to induce IFNγ production, type II interferon that plays ... Endometrial IL-18 receptor mRNA and the ratio of IL-18 binding protein to interleukin 18 are significantly increased in ...
To prove this, several hundred experimental repopulation kinetics from clonal Thy-1lo SCA-1+ lin−(B220, CD4, CD8, Gr-1, Mac-1 ... Using the ratio ρ = L / M {\displaystyle \rho =L/M} of lymphoid (L) to myeloid (M) cells in blood as a quantitative marker, the ... They are round, non-adherent, with a rounded nucleus and low cytoplasm-to-nucleus ratio. In shape, hematopoietic stem cells ... Balanced (Bala) Hematopoietic stem cells repopulate peripheral white blood cells in the same ratio of myeloid to lymphoid cells ...
Both of these vaccines harness the immune system by inducing killer CD8 T cells and cytotoxic CD4 T cells to clear cancer cells ... 1 April 2008). "Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which ...
Current research tends to focus[citation needed] on Th1 and Th17 which mediate allograft rejection via the CD4 and CD8 T cells ... particularly in telltale ratios, (2) structural compromise of tissue anatomy, varying by tissue type transplanted, and (3) ... December 2008). "A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy". The Journal of ...
... of the initial innate response and create a cytokine environment that results in the recruitment of CD4 T-helper and CD8 ... ALT with ratio of AST:ALT>2:1 while in nonalcoholic steatohepatitis ALT>AST with ratio of ALT:AST>1.5:1. Liver biopsies show ... ALT elevation, and the ratio between AST and ALT are informative of the diagnosis. Ultrasound, CT, and MRI can all identify ... higher AST/ALT ratio, low platelet count, and an ultrasound steatosis score. In the early stages (as with NAFLD and early NASH ...
Class II tetramers have been used for analysis of a variety of human CD4 T cell responses to pathogens, including influenza A, ... Co, M. D., Kilpatrick, E. D. & Rothman, A. L. Dynamics of the CD8 T-cell response following yellow fever virus 17D immunization ... and quantification of these specific T-cell populations due to an improved signal-to-noise ratio not present in prior ... "Detection of autoreactive CD4 T cells using major histocompatibility complex class II dextramers". BMC Immunology. 2011 (12): ...
The association of AS with HLA-B27 suggests the condition involves CD8 T cells, which interact with HLA-B. This interaction is ... Over 85% of people that have been diagnosed with AS are HLA-B27 positive, although this ratio varies from population to ... including possibly an ability to interact with T cell receptors in association with CD4 (usually CD8+ cytotoxic T cell with ...
The disease occurs in individuals (male:female ratio 4:1) of all ages. It presents as a tumor of the head, neck, oral cavity, ... These cells are EBV+ cytotoxic T cells and express CD8, CD3, CD2, TAI1, and granzyme but not CD56. Rarely and mostly in the ... Involved tissues exhibit mature-appearing T cells that express CD4. However, attempts to define diagnostic criteria for PTCL, ... This LPD occurs primarily in middle aged males (male:female ratio 2:1). EBV+ LG usually (~90% of cases) presents as a lung ...
Lck is anchored to the plasma membrane by associating with the co-receptor CD4 or CD8, depending on the T cell subtype. CD4 is ... This ratio changes during ontogeny and in diseased states (such as leukemia). It also differs between species. Orthologues of ... CD8, on the other hand, specific for MHC class I, is expressed on cytotoxic T cells. Binding of the co-receptor to the MHC ... November 2013). "A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4(+) T cells ...
"Concurrent interaction of DCs with CD4+and CD8+T cells improves secondary CTL expansion: It takes three to tango". European ... The morphology of dendritic cells results in a very large surface-to-volume ratio. That is, the dendritic cell has a very large ... IL-12 is a signal that helps send naive CD4 T cells towards a Th1 phenotype. The ultimate consequence is priming and activation ... Smith, C. M.; Wilson, N. S.; Waithman, J; Villadangos, J. A.; Carbone, F. R.; Heath, W. R.; Belz, G. T. (2004). "Cognate CD4 ...
Skin-resident memory CD8⁺ T cells trigger a state of tissue-wide pathogen alert". Science. 346 (6205): 101-5. doi:10.1126/ ... Autoreactive TRM cells and reduced ratio or activity of regulatory T cells (Tregs) which protects body from autoimmunity by ... Tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection". Journal of Immunology. 187 ... McMaster, Sean R.; Wilson, Jarad J.; Wang, Hong; Kohlmeier, Jacob E. (2015-07-01). "Airway-Resident Memory CD8 T Cells Provide ...
... as well as proteins such as CD4, subsequently termed first generation CARs. A first generation CAR containing a CD4 ... CAR T cells can be both CD4+ and CD8+, with a 1-to-1 ratio of both cell types providing synergistic antitumor effects. CAR T ... Hinge sequences are often based on membrane-proximal regions from other immune molecules including IgG, CD8, and CD28. The ...
CD4, CD8, and CD20 in Decidual and Trophoblastic Tissue Specimens of Patients with Recurrent Pregnancy Loss. Clin Pract. 2022 ... As an example, Celiac disease increases the risk of miscarriage by an odds ratio of approximately 1.4. A disruption in normal ... The presence of anti-thyroid autoantibodies is associated with an increased risk with an odds ratio of 3.73 and 95% confidence ...
All T cells begin as CD4-CD8-TCR- cells at the DN (double-negative) stage, where an individual cell will rearrange its T cell ... it is now widely recognized that the ratio of Treg to effector T cells in the tumor microenvironment is a determining factor in ... If they receive these signals, they proliferate and express both CD4 and CD8, becoming double-positive cells. The selection of ... Regulatory T cells come in many forms with the most well-understood being those that express CD4, CD25, and FOXP3 (CD4+CD25+ ...
CD4/CD8 Ratio could be predictor of burden hepatocellular carcinoma in Egyptian chronic hepatitis C after combined sofosbuvir ... Long follow up revealed 26.6% developed focal HCC, in more addition, multivariate analysis show CD4/CD8 ratio could be ... CD4/CD8 Ratio could be predictor of burden hepatocellular carcinoma in Egyptian chronic he ... 26.6% developed focal HCC with independent CD4/CD8 predictor for burden malignancy. Further large extended population study is ...
The CD4/CD8 ratio (0.73; normal 0.88-1.84) was low, and complete suppression of immunoglobulin was observed, with decreased ...
A CD4 count measures the number of CD4 cells in your blood. Its used to check the immune system function in people with HIV. ... cd8_ratio. *U.S. Department of Veterans Affairs [Internet]. Washington D.C.: U.S. Department of Veterans Affairs; CD4 count (or ... What is a CD4 count?. A CD4 count is a blood test that measures the number of CD4 cells in a sample of your blood. CD4 cells ... Health Encyclopedia: CD4-CD8 Ratio; [cited 2022 May 4]; [about 4 screens]. Available from: https://www.urmc.rochester.edu/ ...
... and the CD4:CD8 T cell ratio in these sites for each donor. The CD4:CD8 T cell ratio within ILFs of jejunum and colon was not ... There was a progressive increase in the CD4:CD8 T ratio from mucosal sites, GALT to mLNs, with an overall lower CD4:CD8 content ... d Mean frequencies ± s.e.m. of CD4+ CD69+ (top), CD4+CD69+CD103+ (second row from the top), CD8+CD69+ (third row from the top ... Conversely, CD4+ and CD8+ TEM and CD8+ TEMRA frequency increased with age in all mLN sites and the colon (Fig. 6b, d). Together ...
Cerebrospinal fluid CD4(+)/CD8(+)ratio in diagnosing neurosarcoidosis Sara Nordström, Bengt Andersson, Clas Malmeström Acta ...
Genetic control of the CD4/CD8 T-cell ratio in humans. Nat Med, 1995. 1(12): p. 1279-83. ...
Categories: CD4-CD8 Ratio Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, CopyrightRestricted 9 ...
In F(1) females, the percentages of CD4(-)CD8(+) and CD4(-)CD8(-) thymocytes (25 and 250 ppm), and CD4(+)CD8(-) and CD4(+)CD8 ... CD4-CD8 Ratio Actions. * Search in PubMed * Search in MeSH * Add to Search ... the number of CD4(+)CD8(+) and CD4(-)CD8(+) thymocytes (25 ppm), and the number of splenic T cell subsets and NK cells (25 and ... In contrast, the percentage and number of CD4(+)CD8(+) thymocytes were decreased (250 ppm). Exposure to GEN decreased the ...
Combination of standard doses of didanosine and tenofovir may have contributed to the CD4 cell decline o … ... CD4-CD8 Ratio Actions. * Search in PubMed * Search in MeSH * Add to Search ... Combination of standard doses of didanosine and tenofovir may have contributed to the CD4 cell decline observed with this QD ... CD4 count decreased in the QD Group, with a mean decline of 95 cells/mm3 (95% CI: 45-145). Twelve subjects in the QD Group (14 ...
... an increase of CD4+ cells such that the CD4/CD8 ratio is ,10, and/or an expansion of T cells with a loss of one or more of the ... expanded CD4+ T-cell population resulting in CD4/CD8 ratio of ,10; loss of any or all of T-cell antigens CD2, CD3, CD4, and CD5 ... The atypical cells show a CD3+, CD4−, CD8+, and CD30− T-cell phenotype with variable loss of pan-T-cell antigens (CD2, CD5, CD7 ... CD4-CD8-"Double-negative" cutaneous T-cell lymphomas share common histologic features and an aggressive clinical course. Am J ...
CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J AIDS 1989;2:114-24. 18. CDC. ... CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus infected individuals. Ann Intern Med (in ...
Changes in CD4/CD8 ratio after SB-728mR-HSPC infusion [ Time Frame: Up to Year 5 ]. *Detection of CCR5-modified PBMC in blood ... At 9-12 months after SB-728mR-HSPC infusion, subjects who are aviremic with CD4 cell counts ≥600 cells/µL and have ≥1% CCR5- ... modified CD4 cells within the peripheral blood detected by pentamer PCR will undergo an ATI. ...
Kantrow SP, Meyer KC, Kidd P, et al. The CD4/CD8 ratio in BAL fluid is highly variable in sarcoidosis. Eur Respir J 1997;10: ... while bronchoalveolar lavage with CD4/CD8 counting is variable and less sensitive 20. ... US to have a very unfavourable risk/benefit ratio in particular cases. As a result, 33 (24%) patients were left without a ...
staining was performed with anti-CD3, CD4,. CD8, and Granzyme B (GrB). The CD4+:CD8+ and GrB+:CD8. ratios were determined.. ... ratio showed different patterns in recurrent and nonrecurrent. tumors, which is why it could become a useful. a prognostic ... GrB+:CD8+ ratios were significantly higher in patients without. recurrent disease (P = 0.0002, P = 0.039, respectively).. ...
6. CD4/CD8 Ratio and Cancer Risk Among Adults With HIV.. Castilho JL; Bian A; Jenkins CA; Shepherd BE; Sigel K; Gill MJ; ...
CD4+FOXP3-; n. = 46; left) cells and Tregs (CD4+FOXP3+; n. = 46; right) among all CD4+ T cells. (. F. ) Ratio of CD8+ T cells ... Quantification of CD8+ (. n. = 71; left) and CD4+ (. n. = 71; right) among all CD3+ T cells and (. E. ) conventional CD4+ T ( ... 46; left) and CD4+ Tconv cells to Tregs (. n. = 46; right). Each point represents data from 1 patient. Medians are shown as ... Neoadjuvant chemotherapy increases the frequency of tumor-infiltrating CD4+ Tconv cells and reduces the proportion of Tregs. ...
CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J AIDS 1989;2:114-24. * CDC. ... CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus infected individuals. Ann Intern Med (in ...
CD3+CD4-CD8- Double Negative αβ T cells Attenuate Lung Ischemia-Reperfusion Injury. J Thorac Cardiovasc Surg. 2019 Nov 2; [Epub ... Elevated neutrophil to lymphocyte ratio is associated with poor long-term survival and graft failure after lung transplantation ...
Prognosis Prediction in START Similar with IL-6, D-dimer, CD8s, and CD4:CD8 Ratio - Mark Mascolini (03/23/18). ... Methotrexate Reins in CD8 Cells But Does Not Improve Endothelial Function - Mark Mascolini (03/12/18). ... P38 MAPK in vivo inhibition impacts SIV-mediated immune activation & CD4 T-cell loss (03/16/18). ... Distribution of Active PrEP Prescriptions and the PrEP-to-Need Ratio, US Q2 2017 - (03/07/18). ...
CD4-CD8 Ratio Preferred Concept UI. M0025210. Scope Note. Ratio of T-LYMPHOCYTES that express the CD4 ANTIGEN to those that ... CD4 Lymphocyte Count [E01.370.225.500.195.107.595.500.150] * CD4-CD8 Ratio [E01.370.225.500.195.107.595.500.150.160] ... CD4 Lymphocyte Count [E01.370.225.625.107.595.500.150] * CD4-CD8 Ratio [E01.370.225.625.107.595.500.150.160] ... CD4 Lymphocyte Count [E05.200.500.195.107.595.500.150] * CD4-CD8 Ratio [E05.200.500.195.107.595.500.150.160] ...
The CD4/CD8 T lymphocyte ratio may remain abnormal for prolonged periods after transplantation, and persistent functional ... homeostasis in HIV-infected individuals or in relevant animal models and gene-based therapies to normalize the CD4/CD8 ratio. o ...
The inverted CD4:CD8 ratio is associated with gender-related changes in oxidative stress during aging. Cell Immunol 2015;296: ... CD4+ and CD8+ T cell cytokine profiles in response to spike and SEB after the booster dose (T3). (A, B) CD4+ and CD8+ T-cell ... Temporal evolution of CD4+ and CD8+ T cell cytokine profiles in response to spike and SEB stimuli. (A, B) CD4+ and CD8+ T-cell ... Cd4+ and CD8+ T-cell memory phenotype after booster. We characterised the CD4+ and CD8+ memory T cells at T3 according to the ...
The one small study on women pre-ART demonstrated that trauma predicted decreased CD4/CD8 ratios. She noted that that there are ... The role of gut CD4 cells in specific subsets and/or other gut cells as a potential reservoir for HIV in patients on ... These changes include: the increase in the ratio of uterus to cervix size; modifications in cervical tissue from single layer ...
Additionally, there was a distinct decrease in splenic CD4+CD8- T-cells resulting in a concomitant decrease in the CD4+:CD8+ ... ratio. At 56-days of age, the most striking effect was noted with increased NK cell activity in both treatment groups. ...
Flow cytometry showed "T-cells with increased CD4:CD8 ratio (8:1), but otherwise an unremarkable phenotype and a polytypic B- ...
... and CD4/CD8 ratio reported.. "The novelty of the present study lies in the fact that this is the first report on the positive ...
  • They're also called CD4 T lymphocytes or "helper T cells. (medlineplus.gov)
  • A low ratio of CD4+ (helper) any chromosomal or hereditary disorder lymphocytes relative to CD8+ (suppressor) that caused the malnutrition. (who.int)
  • Ratio of T-LYMPHOCYTES that express the CD4 ANTIGEN to those that express the CD8 ANTIGEN . (nih.gov)
  • Although total leukocyte count remained unchanged, there was a decrease in the CD4 T/CD8 T-cell ratio as well as in the percentage of mature T lymphocytes, probably because of a decrease in both the percentage and absolute number of T helper cells. (erowid.org)
  • The decrease in CD4 T-cell counts and in the functional responsiveness of lymphocytes to mitogenic stimulation was dose-dependent. (erowid.org)
  • CD3+ lymphocytes, CD4 T-cells, and the percent of CD3+HLA-DR+ activated lymphocytes increased significantly with Dzherelo but not in the other group. (thecamreport.com)
  • The Dutch BAL working party initiated an investigation to evaluate the diagnostic value of relative number of CD103 expressing CD4+T-lymphocytes in the BAL fluid of patients with a variety of interstitial lung diseases. (eur.nl)
  • We redefined criteria for alveolar CD4+T-cell lymphocytosis and for the relative enumeration of CD103 expressing CD4+T-lymphocytes in the BAL fluid. (eur.nl)
  • A normal CD4/CD8 ratio is greater than 1.0, with CD4 lymphocytes ranging from 500 to 1200/mm 3 and CD8 lymphocytes ranging from 150 to 1000/mm 3. (fabulousfrocksofatlanta.com)
  • The levels of TILs, including the total number of T cells, cluster of differentiation (CD)4 + T cells, CD8 + cytotoxic T lymphocytes (CTLs), regulatory T‑cells (Tregs), programmed cell death protein 1 + T cells and programmed cell death ligand 1 (PD‑L1) + T cells, in the TME of patients with PC were detected using multiple fluorescence immunohistochemistry. (spandidos-publications.com)
  • In F(1) males, GEN increased the terminal body and spleen weights (25 and 250 ppm), the number of CD4(+)CD8(+) and CD4(-)CD8(+) thymocytes (25 ppm), and the number of splenic T cell subsets and NK cells (25 and 250 ppm). (nih.gov)
  • Additionally, there was a distinct decrease in splenic CD4+CD8- T-cells resulting in a concomitant decrease in the CD4+:CD8+ ratio. (cdc.gov)
  • Examination of the organ weights and splenic phenotypes showed that TCDD exposure increased the spleen/body weight ratio, decreased the thymus/body weight ratio, and decreased the percentage of splenic CD3+/CD4-CD8- cells in both genders. (nih.gov)
  • immunological tests including total T cell count, T helper cell count, T cytotoxic cell count and natural killer cell count in peripheral blood through (CD3, CD3/CD4, CD3/CD8 and CD56 respectively) by Fluorochrome monoclonal antibodies labelled with specific dyes through Multiparameter, FACSCanto ™ II flow cytometer (Becton Dickinson, USA). (bvsalud.org)
  • CD4 helper T-cells which alert the immune the studied infants were from low socio- system to an attack by a pathogen and the economic status families according to the CD8 suppressor T-cells which destroy cells classification of Park and Park [11]. (who.int)
  • It compares the proportion of so-called "helper" CD4 T cells to "killer" CD8 T cells, the value of which can help predict the likely course of the disease. (fabulousfrocksofatlanta.com)
  • Elevated neutrophil to lymphocyte ratio is associated with poor long-term survival and graft failure after lung transplantation. (hopkinsmedicine.org)
  • Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute exacerbation of COPD. (ers-education.org)
  • CD4/CD8 Ratio could be predictor of burden hepatocellular carcinoma in Egyptian chronic hepatitis C after combined sofosbuvir and daclatasvir therapy. (bvsalud.org)
  • Long follow up revealed 26.6% developed focal HCC, in more addition, multivariate analysis show CD4/CD8 ratio could be predictor as well as sex for early development of HCC after combined DAAS therapy . (bvsalud.org)
  • 26.6% developed focal HCC with independent CD4/CD8 predictor for burden malignancy . (bvsalud.org)
  • The CD4+:GrB+ and GrB+:CD8+ ratios were significantly higher in patients without recurrent disease (P = 0.0002, P = 0.039, respectively). (srce.hr)
  • The CD4/CD8 cell ratio improved significantly with Dzherelo but not in the other group. (thecamreport.com)
  • Compared with paracancerous tissues, in PC tissues, the proportions of total T cells, CD4 + T cells and CD8 + CTLs were markedly decreased, while those of Tregs and PD‑L1 + T cells were significantly increased. (spandidos-publications.com)
  • A CD4 count is a blood test that measures the number of CD4 cells in a sample of your blood. (medlineplus.gov)
  • CD4 cells are a type of white blood cell. (medlineplus.gov)
  • HIV attacks and destroys CD4 cells. (medlineplus.gov)
  • Without treatment, HIV may destroy so many CD4 cells that your immune system will have trouble fighting off infections. (medlineplus.gov)
  • A CD4 count may be used with other tests to find out which type of immune cells are causing lymphoma. (medlineplus.gov)
  • CD4 results are usually given as a number of cells per cubic millimeter of blood. (medlineplus.gov)
  • A CD4 count of 200 or fewer cells per cubic millimeter means that you have AIDS. (medlineplus.gov)
  • Nevertheless, CD4 count decreased in the QD Group, with a mean decline of 95 cells/mm3 (95% CI: 45-145). (nih.gov)
  • At 9-12 months after SB-728mR-HSPC infusion, subjects who are aviremic with CD4 cell counts ≥600 cells/µL and have ≥1% CCR5-modified CD4 cells within the peripheral blood detected by pentamer PCR will undergo an ATI. (clinicaltrials.gov)
  • Neoadjuvant chemotherapy increases the frequency of tumor-infiltrating CD4 + Tconv cells and reduces the proportion of Tregs. (jci.org)
  • right) among all CD4 + T cells. (jci.org)
  • CD3+CD4-CD8- Double Negative αβ T cells Attenuate Lung Ischemia-Reperfusion Injury. (hopkinsmedicine.org)
  • Compared with HCWs, PwMS presented a higher frequency of CD4 + and CD8 + terminally differentiated effector memory cells and of CD4 + effector memory (T EM ) cells, independently of the stimulus suggesting the association of this phenotype with MS status. (bmj.com)
  • Levels of human (h) IgE, amount of B-, T- and plasma-cells and ratio of CD4 : CD8 positive cells served as read out for induction and inhibition of cell proliferation and hIgE secretion. (uni-wuerzburg.de)
  • The dynamics of CD4 and CD8 T cells are altered in many ways during HIV infection. (fabulousfrocksofatlanta.com)
  • Although both show evidence of increased proliferation and preferential loss of the naive subset, there is depletion of CD4 T cells and expansion of CD8 T cells (1-5). (fabulousfrocksofatlanta.com)
  • It is important to note that the infiltrates of total T cells, CD4 + T cells, Tregs and PD‑L1 + T cells in the TME were independent risk factors for the prognosis of PC. (spandidos-publications.com)
  • PC was characterized by an immunosuppressive TME with a decrease in the number of CD4 + T cells and CD8 + CTLs, and an increase in the number of Tregs and PD‑L1 + T cells. (spandidos-publications.com)
  • Overall, the number of total T cells, CD4 + T cells, Tregs and PD‑L1 + T cells in the TME was a potential predictive marker for the prognosis of PC. (spandidos-publications.com)
  • We compared the expression profile of PD-L1/PD-1 axis on CD138 + cells, CD14 + monocytes and T cells (both CD4 + and CD8 + ), by flow-cytometry. (confex.com)
  • Among the cytokines tested on the total cohort, the anti-tumoral IL-27 BM serum levels inversely correlated with PD-L1 MFI only on CD14 + cells (p=0.025), with CD8 + PD-1 + % (p=0.013) and with the immunesuppressive cytokine IL-10 serum levels (p=0.035), independently from the stage of disease. (confex.com)
  • Focusing on patients with active MM, those with ISS=II and III showed increased PD-L1 expression on CD14 + cells (ISS II+III vs I, median MFI 20.35 vs 14.59, p=0.005) and higher CD8 + PD-1 + % (II+III vs I, 4.35 vs 2.58, p=0.022) compared with ISS=I patients. (confex.com)
  • CD4 counts can help monitor your risk for developing opportunistic infections or certain cancers. (medlineplus.gov)
  • If you are taking medicine for HIV, your provider may order regular CD4 counts with an HIV viral load test to see how well your medicines are working. (medlineplus.gov)
  • But labs may have different ways of describing "normal" CD4 counts. (medlineplus.gov)
  • CD4 counts may change even when your health has not changed. (medlineplus.gov)
  • So, your provider will usually look at a few test results over time to see if there's a trend in your CD4 counts. (medlineplus.gov)
  • Among the changes to CTCL classification were the addition of primary cutaneous acral CD8 + T-cell lymphoma as a new provisional entity. (medscape.com)
  • Also, the term "primary cutaneous CD4 + small/medium T-cell lymphoma" was changed to "primary cutaneous CD4 + small/medium T-cell lymphoproliferative disorder" because of its indolent clinical behavior and uncertain malignant potential. (medscape.com)
  • The levels of CD4 + T cell and CD8 + CTL infiltrates were inversely associated with tumor differentiation. (spandidos-publications.com)
  • TIL subset ratio showed different patterns in recurrent and nonrecurrent tumors, which is why it could become a useful a prognostic clinical index if our findings are confirmed in randomized trials. (srce.hr)
  • In PwMS, total Th1 and IFN-γ CD4 + T-cell responders to spike protein were increased from T2 to T3. (bmj.com)
  • Combined MDMA and alcohol produced the greatest suppressive effect on CD4 T-cell count and PHA-stimulated lymphoproliferation. (erowid.org)
  • The CD4 cell count of a person who does not have HIV can be anything between 500 and 1500. (fabulousfrocksofatlanta.com)
  • People living with HIV who have a CD4 cell count below 200 are at high risk of developing serious illnesses. (fabulousfrocksofatlanta.com)
  • A high CD4+/CD8+ratio in bronchoalveolar lavage fluid is indicative for the diagnosis pulmonary sarcoidosis but this ratio only does not fully discriminate pulmonary sarcoidosis from other interstitial lung diseases. (eur.nl)
  • Why is CD8 high in HIV? (fabulousfrocksofatlanta.com)
  • What does a high CD4 CD8 ratio mean? (fabulousfrocksofatlanta.com)
  • The CD4/CD8 ratio is one of the blood tests used to monitor your immune system if you have human immunodeficiency virus (HIV). (fabulousfrocksofatlanta.com)
  • In addition, the researchers report that the black cumin oil extract also modulate immunity status, with changes in immunoglobulins, cytokines, and CD4+, CD8+, and CD4/CD8 ratio reported. (nutraingredients.com)
  • 6. CD4/CD8 Ratio and Cancer Risk Among Adults With HIV. (nih.gov)
  • A low or inverted CD4/CD8 ratio is an immune risk phenotype and is associated with altered immune function, immune senescence, and chronic inflammation in both HIV-infected and uninfected populations [8-11]. (fabulousfrocksofatlanta.com)
  • IL-4 shifted CD4 : CD8 ratios in vitro and in vivo when hPBMC derived from healthy volunteers were used. (uni-wuerzburg.de)
  • Total CD4 + T-cell counts predict HIV disease progression but do not necessarily reflect normalization of immune function. (medscape.com)
  • Individuals with higher CD4/CD8 ratio at seroconversion were significantly less likely to reach the disease progression endpoint [adjusted hazard ratio (aHR) (95% CI) = 0.52 (0.32 to 0.82), P = 0.005]. (medscape.com)
  • CD4/CD8 ratio is a marker of immune dysfunction, a prognostic indicator for non-AIDS mortality, and reflects viral reservoir size. (medscape.com)
  • A CD4 count is mostly used to check the health of your immune system if you are infected with HIV (human immunodeficiency virus). (medlineplus.gov)
  • Without treatment, HIV may destroy so many CD4 cells that your immune system will have trouble fighting off infections. (medlineplus.gov)
  • A CD4 count may also be used to help diagnose and monitor certain other conditions that affect your immune system. (medlineplus.gov)
  • A CD4 count may be used with other tests to find out which type of immune cells are causing lymphoma. (medlineplus.gov)
  • If you have HIV , a low CD4 count means that HIV has weakened your immune system. (medlineplus.gov)
  • CD4 helper T-cells which alert the immune the studied infants were from low socio- system to an attack by a pathogen and the economic status families according to the CD8 suppressor T-cells which destroy cells classification of Park and Park [11]. (who.int)
  • 20. Underestimation of relative risks by standardized incidence ratios for AIDS-related cancers. (nih.gov)
  • we hypothesize enhanced CD4/CD8 ratio recovery with earlier treatment initiation in recently infected individuals. (medscape.com)